| 1 |
Saha S, González-Maeso J. The crosstalk between 5-HT(2A)R and mGluR2 in schizophrenia. Neuropharmacology 2023;230:109489. [PMID: 36889432 DOI: 10.1016/j.neuropharm.2023.109489] [Reference Citation Analysis]
|
| 2 |
Ngo HV, Oster H, Andreou C, Obleser J. Circadian rhythms in auditory hallucinations and psychosis. Acta Physiol (Oxf) 2023;237:e13944. [PMID: 36744985 DOI: 10.1111/apha.13944] [Reference Citation Analysis]
|
| 3 |
Nakamura T, Takata A. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Mol Psychiatry 2023. [PMID: 36878965 DOI: 10.1038/s41380-023-02005-2] [Reference Citation Analysis]
|
| 4 |
Abad-perez P, F.j. M, Martínez-otero L, Borrell V, Redondo R, Brotons-mas J. Theta/gamma co-modulation disruption after nmdar blockade by mk801 is associated with spatial working memory deficits in mice. Neuroscience 2023. [DOI: 10.1016/j.neuroscience.2023.03.022] [Reference Citation Analysis]
|
| 5 |
Dang X, Liu J, Zhang Z, Luo XJ. Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Identifies Novel Risk Genes for Schizophrenia. Mol Neurobiol 2023;60:1537-46. [PMID: 36517655 DOI: 10.1007/s12035-022-03160-3] [Reference Citation Analysis]
|
| 6 |
Göverti D, Büyüklüoğlu N, Nazik Yüksel R, Kaya H, Yücel Ç, Göka E. Decreased serum levels of α-synuclein in patients with schizophrenia and their unaffected siblings. Early Interv Psychiatry 2023. [PMID: 36707089 DOI: 10.1111/eip.13398] [Reference Citation Analysis]
|
| 7 |
McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry 2023. [PMID: 36690793 DOI: 10.1038/s41380-023-01949-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Fišar Z. Biological hypotheses, risk factors, and biomarkers of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2023;120:110626. [PMID: 36055561 DOI: 10.1016/j.pnpbp.2022.110626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Dixon TA, Muotri AR. Advancing preclinical models of psychiatric disorders with human brain organoid cultures. Mol Psychiatry 2023;28:83-95. [PMID: 35948659 DOI: 10.1038/s41380-022-01708-2] [Reference Citation Analysis]
|
| 10 |
Braslow JT. Nosologies/Diagnostic Systems. The Palgrave Handbook of the History of Human Sciences 2023. [DOI: 10.1007/978-981-15-4106-3_92-1] [Reference Citation Analysis]
|
| 11 |
Xue K, Chen J, Wei Y, Chen Y, Han S, Wang C, Zhang Y, Song X, Cheng J. Altered static and dynamic functional connectivity of habenula in first-episode, drug-naïve schizophrenia patients, and their association with symptoms including hallucination and anxiety. Front Psychiatry 2023;14:1078779. [PMID: 36741115 DOI: 10.3389/fpsyt.2023.1078779] [Reference Citation Analysis]
|
| 12 |
Waters F. The future of hallucination research: Can hallucinogens and psychedelic drugs teach us anything? Psychiatry Res 2023;319:114968. [PMID: 36462291 DOI: 10.1016/j.psychres.2022.114968] [Reference Citation Analysis]
|
| 13 |
Bespalov A, van Gaalen M, Steckler T. Back to the Future of Neuropsychopharmacology. Adv Neurobiol 2023;30:207-24. [PMID: 36928852 DOI: 10.1007/978-3-031-21054-9_9] [Reference Citation Analysis]
|
| 14 |
Taylor D, Chithiramohan R, Grewal J, Gupta A, Hansen L, Reynolds GP, Pappa S. Dopamine partial agonists: a discrete class of antipsychotics. Int J Psychiatry Clin Pract 2022;:1-13. [PMID: 36495086 DOI: 10.1080/13651501.2022.2151473] [Reference Citation Analysis]
|
| 15 |
Jackson TB, Damme KSF, Mittal VA, Bernard JA. Cerebello-Basal Ganglia Functional Network Integration in Psychosis.. [DOI: 10.1101/2022.11.12.516285] [Reference Citation Analysis]
|
| 16 |
Jackson TB, Bernard JA. Cerebellar and basal ganglia motor network predicts trait depression and hyperactivity. Front Behav Neurosci 2022;16:953303. [DOI: 10.3389/fnbeh.2022.953303] [Reference Citation Analysis]
|
| 17 |
Biernat L, Grattan VT, Hixon MS, Prensky Z, Vaino AR. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D(2/3)/5-HT(7) inhibitor. Psychopharmacology (Berl) 2022;239:3009-18. [PMID: 35841422 DOI: 10.1007/s00213-022-06185-7] [Reference Citation Analysis]
|
| 18 |
Wang X, Xiu M, Wang K, Su X, Li X, Wu F. Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia. Metabolomics 2022;18:50. [PMID: 35819637 DOI: 10.1007/s11306-022-01909-4] [Reference Citation Analysis]
|
| 19 |
Lin P, Sun J, Lou X, Li D, Shi Y, Li Z, Ma P, Li P, Chen S, Jin W, Liu S, Chen Q, Gao Q, Zhu L, Xu J, Zhu M, Wang M, Liang K, Zhao L, Xu H, Dong K, Li Q, Cheng X, Chen J, Guo X. Consensus on potential biomarkers developed for use in clinical tests for schizophrenia. Gen Psych 2022;35:e100685. [DOI: 10.1136/gpsych-2021-100685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Millard SJ, Bearden CE, Karlsgodt KH, Sharpe MJ. The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity. Neuropsychopharmacology 2022;47:628-40. [PMID: 34588607 DOI: 10.1038/s41386-021-01188-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 21 |
Ravichandran-schmidt P, Hass J. Testing the state-dependent model of time perception against experimental evidence.. [DOI: 10.1101/2021.12.31.474629] [Reference Citation Analysis]
|
| 22 |
Vasquez AR, Bobo WV. Mood Stabilizers: Risperidone for Treating Bipolar Disorders in Adults. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-030-62059-2_48] [Reference Citation Analysis]
|
| 23 |
Tepper Á, Cuiza A, Alliende LM, Mena C, Ramirez-Mahaluf JP, Iruretagoyena B, Ornstein C, Fritsch R, Nachar R, González-Valderrama A, Undurraga J, Cruz JP, Tejos C, Fornito A, Repetto G, Crossley N. Functional Dysconnectivity in Ventral Striatocortical Systems in 22q11.2 Deletion Syndrome. Schizophr Bull 2022;48:485-94. [PMID: 34931688 DOI: 10.1093/schbul/sbab139] [Reference Citation Analysis]
|
| 24 |
Lee D, Seo J, Jeong HC, Lee H, Lee SB. The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons. Front Mol Neurosci 2021;14:756613. [PMID: 34867186 DOI: 10.3389/fnmol.2021.756613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Vilela-Filho O, Ragazzo PC, Canêdo D, Barreto US, Oliveira PM, Goulart LC, Reis MD, Campos TM. The impact of subcaudate tractotomy on delusions and hallucinations in psychotic patients. Surg Neurol Int 2021;12:475. [PMID: 34621590 DOI: 10.25259/SNI_599_2021] [Reference Citation Analysis]
|
| 26 |
Hansen N, Lipp M, Vogelgsang J, Vukovich R, Zindler T, Luedecke D, Gingele S, Malchow B, Frieling H, Kühn S, Denk J, Gallinat J, Skripuletz T, Moschny N, Fiehler J, Riedel C, Wiedemann K, Wattjes MP, Zerr I, Esselmann H, Bleich S, Wiltfang J, Neyazi A; CAP (Cerebrospinal Fluid Analysis in Psychiatry) Consortium. Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. Brain Behav Immun Health 2020;9:100154. [PMID: 34589896 DOI: 10.1016/j.bbih.2020.100154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 27 |
Nicotera AG, Di Rosa G, Turriziani L, Costanzo MC, Stracuzzi E, Vitello GA, Rando RG, Musumeci A, Vinci M, Musumeci SA, Calì F. Role of COMT V158M Polymorphism in the Development of Dystonia after Administration of Antipsychotic Drugs. Brain Sci 2021;11:1293. [PMID: 34679357 DOI: 10.3390/brainsci11101293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Abad-perez P, Martínez-otero L, Borrell V, Redondo R, Brotons-mas J. NMDAr Blocking by MK801 Alters Hippocampal and Prefrontal Cortex Oscillations and Impairs Spatial Working Memory in Mice.. [DOI: 10.1101/2021.09.22.461383] [Reference Citation Analysis]
|
| 29 |
Aryutova K, Stoyanov D. Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders. Int J Mol Sci 2021;22:9309. [PMID: 34502214 DOI: 10.3390/ijms22179309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatr 2021; 11(7): 277-296 [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 31 |
Seeman MV. History of the dopamine hypothesis of antipsychotic action. World J Psychiatr 2021; 11(7): 355-364 [PMID: 34327128 DOI: 10.5498/wjp.v11.i7.355] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 32 |
Moon SY, Kim M, Lho SK, Oh S, Kim SH, Kwon JS. Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation. Psychiatry Investig 2021;18:486-99. [PMID: 34218638 DOI: 10.30773/pi.2020.0438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
Benussi A, Dell'Era V, Cantoni V, Cotelli MS, Cosseddu M, Spallazzi M, Alberici A, Padovani A, Borroni B. Neurophysiological Correlates of Positive and Negative Symptoms in Frontotemporal Dementia. J Alzheimers Dis 2020;73:1133-42. [PMID: 31884481 DOI: 10.3233/JAD-190986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 34 |
Ablordeppey S, Ofori E. Antipsychotic Agents. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc103.pub3] [Reference Citation Analysis]
|
| 35 |
Acharya S, Kim KM. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease. Int J Mol Sci 2021;22:4299. [PMID: 33919025 DOI: 10.3390/ijms22094299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 36 |
Hansen N. Locus Coeruleus Malfunction Is Linked to Psychopathology in Prodromal Dementia With Lewy Bodies. Front Aging Neurosci 2021;13:641101. [PMID: 33732141 DOI: 10.3389/fnagi.2021.641101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 37 |
Okazaki S, Boku S, Otsuka I, Horai T, Kimura A, Shimmyo N, Yamaki N, Hishimoto A. Clozapine increases macrophage migration inhibitory factor (MIF) expression via increasing histone acetylation of MIF promoter in astrocytes. J Psychiatr Res 2021;135:237-42. [PMID: 33508542 DOI: 10.1016/j.jpsychires.2021.01.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, Carnovale C. Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review. Int J Neuropsychopharmacol 2021;24:477-89. [PMID: 33575781 DOI: 10.1093/ijnp/pyab005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 39 |
Benrimoh D, Sheldon A, Sibarium E, Powers AR. Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction. Front Psychiatry 2021;12:685390. [PMID: 34385938 DOI: 10.3389/fpsyt.2021.685390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 40 |
Bacil RP, de O. Marcondes Filho EA, de A. Dias K, Portes MC, de Araujo WR, Oliveira-silva D, dos Santos AA, Serrano SH. The chemical interaction between the neurotransmitter dopamine and the antipsychotic drugs olanzapine and quetiapine. Journal of Electroanalytical Chemistry 2021;881:114946. [DOI: 10.1016/j.jelechem.2020.114946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 41 |
Sasiadek J, Lowe DJ, Rioux S, George TP. Substance Use Psychosis. Psychotic Disorders 2021. [DOI: 10.1016/b978-0-323-68309-8.00008-4] [Reference Citation Analysis]
|
| 42 |
Andrade YCP, Ropke J, Viana TG, Fanelli C, Minaldi E, Batista LA, Issy AC, Del Bel EA, Rodrigues LCM, Liégeois JF, Moreira FA. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behav Pharmacol 2021;32:2-8. [PMID: 33399294 DOI: 10.1097/FBP.0000000000000595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 43 |
Dolleman-van der Weel MJ, Witter MP. The thalamic midline nucleus reuniens: potential relevance for schizophrenia and epilepsy. Neurosci Biobehav Rev 2020;119:422-39. [PMID: 33031816 DOI: 10.1016/j.neubiorev.2020.09.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 44 |
Devoto P, Sagheddu C, Santoni M, Flore G, Saba P, Pistis M, Gessa GL. Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex. Front Pharmacol 2020;11:588160. [PMID: 33071798 DOI: 10.3389/fphar.2020.588160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 45 |
Krum BN, Molz de Freitas C, Chiapinotto Ceretta AP, Barbosa CP, de Moraes Reis E, Scussel R, da Silva Córneo E, Machado-de-Ávila RA, Boligon AA, Fachinetto R. Kava decreases the stereotyped behavior induced by amphetamine in mice. J Ethnopharmacol 2021;265:113293. [PMID: 32841698 DOI: 10.1016/j.jep.2020.113293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Nullmeier S, Elmers C, D'Hanis W, Sandhu KVK, Stork O, Yanagawa Y, Panther P, Schwegler H. Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems. Brain Struct Funct 2020;225:1719-42. [PMID: 32514634 DOI: 10.1007/s00429-020-02087-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 47 |
Payeur R, Nixon M, Bourin M, Bradwejn J, Legrand J. The potential role of cholecystokinin in schizophrenia: review and update. Eur psychiatr 1993;8:67-78. [DOI: 10.1017/s0924933800001358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 48 |
Waddington JL. Psychosis in Parkinson's disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges. Acta Pharmacol Sin 2020;41:464-70. [PMID: 32139896 DOI: 10.1038/s41401-020-0373-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 49 |
Howell KR, Law AJ. Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development. Schizophr Res 2020;217:95-104. [PMID: 31522868 DOI: 10.1016/j.schres.2019.08.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 50 |
Fritze S, Sambataro F, Kubera KM, Bertolino AL, Topor CE, Wolf RC, Hirjak D. Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage. Eur Neuropsychopharmacol 2020;31:47-57. [PMID: 31780303 DOI: 10.1016/j.euroneuro.2019.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 51 |
Vasquez AR, Bobo WV. Mood Stabilizers: Risperidone for Treating Bipolar Disorders in Adults. NeuroPsychopharmacotherapy 2020. [DOI: 10.1007/978-3-319-56015-1_48-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 52 |
Harvey C. Medical Perspective on Mental Health. Mental Health and Social Work 2020. [DOI: 10.1007/978-981-13-6975-9_4] [Reference Citation Analysis]
|
| 53 |
Quednow BB, Geyer MA, Halberstadt AL. Serotonin and schizophrenia. Handbook of Behavioral Neuroscience 2020. [DOI: 10.1016/b978-0-444-64125-0.00039-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 54 |
Jacobs GR, Voineskos AN. Genetics and Neuroimaging in Schizophrenia. Neuroimaging in Schizophrenia 2020. [DOI: 10.1007/978-3-030-35206-6_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 55 |
Hodgson NW, Waly MI, Trivedi MS, Power-Charnitsky VA, Deth RC. Methylation-related metabolic effects of D4 dopamine receptor expression and activation. Transl Psychiatry 2019;9:295. [PMID: 31719518 DOI: 10.1038/s41398-019-0630-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 56 |
Dahoun T, Nour MM, McCutcheon RA, Adams RA, Bloomfield MAP, Howes OD. The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [(11)C]-(+)-PHNO PET study. Transl Psychiatry 2019;9:287. [PMID: 31712556 DOI: 10.1038/s41398-019-0627-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 57 |
Dahoun T, Pardiñas AF, Veronese M, Bloomfield MAP, Jauhar S, Bonoldi I, Froudist-Walsh S, Nosarti C, Korth C, Hennah W, Walters J, Prata D, Howes OD. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Hum Mol Genet 2018;27:3498-506. [PMID: 29945223 DOI: 10.1093/hmg/ddy242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 58 |
McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci 2019;42:205-20. [PMID: 30621912 DOI: 10.1016/j.tins.2018.12.004] [Cited by in Crossref: 272] [Cited by in F6Publishing: 223] [Article Influence: 68.0] [Reference Citation Analysis]
|
| 59 |
Klaus K, Pennington K. Dopamine and Working Memory: Genetic Variation, Stress and Implications for Mental Health. Processes of Visuospatial Attention and Working Memory 2019. [DOI: 10.1007/7854_2019_113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 60 |
Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, Turkheimer F, Stone J, Egerton A, McGuire P, Kapur S, Howes OD. The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biol Psychiatry 2019;85:79-87. [PMID: 30122287 DOI: 10.1016/j.biopsych.2018.07.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 61 |
Tarakita N, Yoshida K, Sugawara N, Kubo K, Furukori H, Fujii A, Nakamura K, Yasui-Furukori N. Differences in etiological beliefs about schizophrenia among patients, family, and medical staff. Neuropsychiatr Dis Treat 2019;15:137-42. [PMID: 30643412 DOI: 10.2147/NDT.S185483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 62 |
Harvey C. Medical Perspective on Mental Health. Mental Health and Social Work 2019. [DOI: 10.1007/978-981-13-0440-8_4-1] [Reference Citation Analysis]
|
| 63 |
Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol 2017;15:1192-207. [PMID: 28412910 DOI: 10.2174/1570159X15666170413115754] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 64 |
Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr 2018;23:187-91. [PMID: 29954475 DOI: 10.1017/S1092852918001013] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 22.6] [Reference Citation Analysis]
|
| 65 |
Tomasella E, Bechelli L, Ogando MB, Mininni C, Di Guilmi MN, De Fino F, Zanutto S, Elgoyhen AB, Marin-Burgin A, Gelman DM. Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proc Natl Acad Sci U S A 2018;115:3476-81. [PMID: 29531031 DOI: 10.1073/pnas.1719897115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 66 |
Healy D. Neuroleptics and Psychic Indifference: A Review. J R Soc Med 1989;82:615-9. [DOI: 10.1177/014107688908201018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 67 |
Martino M, Magioncalda P, Yu H, Li X, Wang Q, Meng Y, Deng W, Li Y, Li M, Ma X, Lane T, Duncan NW, Northoff G, Li T. Abnormal Resting-State Connectivity in a Substantia Nigra-Related Striato-Thalamo-Cortical Network in a Large Sample of First-Episode Drug-Naïve Patients With Schizophrenia. Schizophr Bull 2018;44:419-31. [PMID: 28605528 DOI: 10.1093/schbul/sbx067] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 68 |
Liu XB, Zhang Y, Wang XY, Hao W. The synergistic effect of dual use of amphetamine-type stimulants and ketamine on drug-induced psychotic symptoms in Chinese synthetic drug users. Oncotarget 2017;8:66569-75. [PMID: 29029537 DOI: 10.18632/oncotarget.16474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 69 |
Kubota M, Nagashima T, Takano H, Kodaka F, Fujiwara H, Takahata K, Moriguchi S, Kimura Y, Higuchi M, Okubo Y, Takahashi H, Ito H, Suhara T. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. Int J Neuropsychopharmacol 2017;20:928-35. [PMID: 29016872 DOI: 10.1093/ijnp/pyx063] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 70 |
Singh H, Assistant Professor, Department of Psychiatry, Ramaiah Medical College, Bengaluru, M RR, A R, Thyloth M. Disulfiram Induced Psychosis. JAD 2017;3:1-3. [DOI: 10.15436/2471-061x-17-042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 71 |
Shimizu S, Sogabe S, Yanagisako R, Inada A, Yamanaka M, Iha HA, Ohno Y. Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. Int J Mol Sci 2017;18:E1416. [PMID: 28671605 DOI: 10.3390/ijms18071416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 72 |
Park SJ, Yang H, Lee SH, Song HS, Park CS, Bae J, Kwon OS, Park TH, Jang J. Dopamine Receptor D1 Agonism and Antagonism Using a Field-Effect Transistor Assay. ACS Nano 2017;11:5950-9. [PMID: 28558184 DOI: 10.1021/acsnano.7b01722] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 73 |
Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in Chemical Neuroscience: Ketamine. ACS Chem Neurosci 2017;8:1122-34. [PMID: 28418641 DOI: 10.1021/acschemneuro.7b00074] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 74 |
Saia-Cereda VM, Santana AG, Schmitt A, Falkai P, Martins-de-Souza D. The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Mol Neuropsychiatry 2017;3:37-52. [PMID: 28879200 DOI: 10.1159/000477299] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 75 |
Nishiyama K, Suzuki H, Maruyama M, Yoshihara T, Ohta H. Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A2A receptor antagonist in mice: A potential role of GPR52 in the function of striatopallidal neurons. Brain Res 2017;1670:24-31. [PMID: 28583861 DOI: 10.1016/j.brainres.2017.05.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 76 |
Xu J, Kurup P, Nairn AC, Lombroso PJ. Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61. Mol Neurobiol 2018;55:3096-111. [PMID: 28466270 DOI: 10.1007/s12035-017-0555-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 77 |
Almamy A, Schwerk C, Schroten H, Ishikawa H, Asif AR, Reuss B. Crossreactivity of an Antiserum Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae with the SNARE-Complex Protein Snap23 Correlates to Impaired Exocytosis in SH-SY5Y Cells. J Mol Neurosci 2017;62:163-80. [PMID: 28462458 DOI: 10.1007/s12031-017-0920-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 78 |
Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in Chemical Neuroscience: Haloperidol. ACS Chem Neurosci 2017;8:444-53. [PMID: 28170220 DOI: 10.1021/acschemneuro.7b00018] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 79 |
Dandash O, Pantelis C, Fornito A. Dopamine, fronto-striato-thalamic circuits and risk for psychosis. Schizophr Res 2017;180:48-57. [PMID: 27595552 DOI: 10.1016/j.schres.2016.08.020] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 80 |
Howes OD, McCutcheon R, Owen MJ, Murray RM. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biol Psychiatry 2017;81:9-20. [PMID: 27720198 DOI: 10.1016/j.biopsych.2016.07.014] [Cited by in Crossref: 335] [Cited by in F6Publishing: 332] [Article Influence: 55.8] [Reference Citation Analysis]
|
| 81 |
Stahl SM. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr 2016;21:355-9. [PMID: 27686027 DOI: 10.1017/S1092852916000602] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 82 |
Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm 2016;2016:3476240. [PMID: 27524864 DOI: 10.1155/2016/3476240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 83 |
Keulen S, Verhoeven J, De Witte E, De Page L, Bastiaanse R, Mariën P. Foreign Accent Syndrome As a Psychogenic Disorder: A Review. Front Hum Neurosci 2016;10:168. [PMID: 27199699 DOI: 10.3389/fnhum.2016.00168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 84 |
Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Prog Neuropsychopharmacol Biol Psychiatry 2016;66:120-35. [PMID: 26739950 DOI: 10.1016/j.pnpbp.2015.12.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 85 |
Borroto-Escuela DO, Pintsuk J, Schäfer T, Friedland K, Ferraro L, Tanganelli S, Liu F, Fuxe K. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia. Ther Adv Psychopharmacol 2016;6:77-94. [PMID: 27141290 DOI: 10.1177/2045125316637570] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 86 |
Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJM, Guest PC, Rahmoune H, Steiner J, Bahn S. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 2016;52:178-86. [PMID: 26541453 DOI: 10.1016/j.bbi.2015.10.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 87 |
Gründer G, Cumming P. The Dopamine Hypothesis of Schizophrenia. The Neurobiology of Schizophrenia 2016. [DOI: 10.1016/b978-0-12-801829-3.00015-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 88 |
Iwatani J, Ishida T, Donishi T, Ukai S, Shinosaki K, Terada M, Kaneoke Y. Use of T1-weighted/T2-weighted magnetic resonance ratio images to elucidate changes in the schizophrenic brain. Brain Behav 2015;5:e00399. [PMID: 26516617 DOI: 10.1002/brb3.399] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 89 |
Bohus B. Neuropeptides in Brain Functions and Dysfunctions. International Journal of Mental Health 2015;9:6-44. [DOI: 10.1080/00207411.1980.11448861] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 90 |
Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res 2015;167:98-107. [PMID: 25583246 DOI: 10.1016/j.schres.2014.12.026] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 19.3] [Reference Citation Analysis]
|
| 91 |
Krebs M. Chapitre 4. Modèles physiopathologiques : modèle neurodéveloppemental, maturation cérébrale et « double hit ». Signes précoces de schizophrénie 2015. [DOI: 10.3917/dunod.krebs.2015.01.0053] [Reference Citation Analysis]
|
| 92 |
Möller M, Swanepoel T, Harvey BH. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. ACS Chem Neurosci 2015;6:987-1016. [PMID: 25794269 DOI: 10.1021/cn5003368] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 93 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Med Hypotheses 2015;85:391-6. [PMID: 26118462 DOI: 10.1016/j.mehy.2015.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 94 |
Reuss B, Schroten H, Ishikawa H, Asif AR. Cross-reactivity of Antibodies Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae With Heat Shock Protein 60 and ATP-Binding Protein Correlates to Reduced Mitochondrial Activity in HIBCPP Choroid Plexus Papilloma Cells. J Mol Neurosci 2015;57:123-38. [PMID: 26080747 DOI: 10.1007/s12031-015-0585-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 95 |
Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci 2015;69:243-58. [PMID: 25296946 DOI: 10.1111/pcn.12242] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 96 |
Andreou C, Bozikas VP, Luedtke T, Moritz S. Associations between visual perception accuracy and confidence in a dopaminergic manipulation study. Front Psychol 2015;6:414. [PMID: 25932015 DOI: 10.3389/fpsyg.2015.00414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 97 |
McClay JL, Vunck SA, Batman AM, Crowley JJ, Vann RE, Beardsley PM, van den Oord EJ. Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration. J Neuroimmune Pharmacol 2015;10:425-34. [PMID: 25850894 DOI: 10.1007/s11481-015-9605-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 98 |
Duan X, Zhang M, Zhang X, Wang F, Lei M. Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors. Journal of Molecular Graphics and Modelling 2015;57:143-55. [DOI: 10.1016/j.jmgm.2015.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 99 |
Caravaggio F, Borlido C, Wilson A, Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [¹¹C]-(+)-PHNO positron emission tomography: A pilot study. Clin Chim Acta 2015;449:60-2. [PMID: 25814099 DOI: 10.1016/j.cca.2015.03.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 100 |
Bobo WV, Rapoport JL, Abi‐dargham A, Hossein Fatemi S, Meltzer HY. The Neurobiology of Schizophrenia. Psychiatry 2015. [DOI: 10.1002/9781118753378.ch19] [Reference Citation Analysis]
|
| 101 |
Fryar-Williams S, Strobel JE. Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res 2015;3:3. [PMID: 25729574 DOI: 10.1186/s40364-015-0028-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 102 |
De Luca MA, Lai F, Corrias F, Caboni P, Bimpisidis Z, Maccioni E, Fadda AM, Di Chiara G. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. Int J Pharm 2015;479:129-37. [PMID: 25560308 DOI: 10.1016/j.ijpharm.2014.12.057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 103 |
Ratnayake U, Basrai HS, Turnley AM, van den Buuse M. Dopaminergic activity and behaviour in SOCS2 transgenic mice: Revealing a potential drug target for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2015;56:247-53. [PMID: 25283341 DOI: 10.1016/j.pnpbp.2014.09.009] [Reference Citation Analysis]
|
| 104 |
Rolland B, Amad A, Poulet E, Bordet R, Vignaud A, Bation R, Delmaire C, Thomas P, Cottencin O, Jardri R. Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia. Schizophr Bull 2015;41:291-9. [PMID: 25053649 DOI: 10.1093/schbul/sbu097] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 105 |
Chen LC, Bai YM, Chang MH. Polydipsia, hyponatremia and rhabdomyolysis in schizophrenia: A case report. World J Psychiatr 2014; 4(4): 150-152 [PMID: 25540730 DOI: 10.5498/wjp.v4.i4.150] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 106 |
Chastain LG, Qu H, Bourke CH, Iuvone PM, Dobner PR, Nemeroff CB, Kinkead B. Striatal dopamine receptor plasticity in neurotensin deficient mice. Behav Brain Res 2015;280:160-71. [PMID: 25449842 DOI: 10.1016/j.bbr.2014.11.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 107 |
van Ruitenbeek P, Mehta MA. Potential enhancing effects of histamine H₁ agonism/H₃ antagonism on working memory assessed by performance and bold response in healthy volunteers. Br J Pharmacol 2013;170:144-55. [PMID: 23517178 DOI: 10.1111/bph.12184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 108 |
Bonoldi I, Howes OD. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis. CNS Drugs 2014;28:649-63. [PMID: 24919790 DOI: 10.1007/s40263-014-0177-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 109 |
Nullmeier S, Panther P, Frotscher M, Zhao S, Schwegler H. Alterations in the hippocampal and striatal catecholaminergic fiber densities of heterozygous reeler mice. Neuroscience 2014;275:404-19. [PMID: 24969133 DOI: 10.1016/j.neuroscience.2014.06.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 110 |
Figueira FH, Leal CQ, de Moraes Reis E, Röpke J, Wagner C, da Rocha JBT, Fachinetto R. Effects of diphenyl diselenide on behavioral and biochemical changes induced by amphetamine in mice. J Neural Transm 2015;122:201-9. [DOI: 10.1007/s00702-014-1257-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 111 |
Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 2014;204:420-9. [PMID: 25029687 DOI: 10.1192/bjp.bp.113.132308] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 112 |
Sellmann C, Villarín Pildaín L, Schmitt A, Leonardi-Essmann F, Durrenberger PF, Spanagel R, Arzberger T, Kretzschmar H, Zink M, Gruber O, Herrera-Marschitz M, Reynolds R, Falkai P, Gebicke-Haerter PJ, Matthäus F. Gene expression in superior temporal cortex of schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2014;264:297-309. [PMID: 24287731 DOI: 10.1007/s00406-013-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 113 |
Andreou C, Moritz S, Veith K, Veckenstedt R, Naber D. Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study. Schizophr Bull 2014;40:558-65. [PMID: 23661634 DOI: 10.1093/schbul/sbt064] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 114 |
Hawken ER, Beninger RJ. The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat. Psychopharmacology (Berl) 2014;231:2001-8. [PMID: 24241687 DOI: 10.1007/s00213-013-3345-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 115 |
McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Altered serine/threonine kinase activity in schizophrenia. Brain Res 2014;1568:42-54. [PMID: 24780530 DOI: 10.1016/j.brainres.2014.04.029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 116 |
Meyer F, Louilot A. Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Front Behav Neurosci 2014;8:118. [PMID: 24778609 DOI: 10.3389/fnbeh.2014.00118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 117 |
Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75:292-9. [PMID: 24439555 DOI: 10.1016/j.biopsych.2013.12.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 118 |
Sabioni P, Ramos AC, Galduróz JC. The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review. Curr Neuropharmacol 2013;11:484-90. [PMID: 24403872 DOI: 10.2174/1570159X11311050003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 119 |
Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013;123:4986-91. [PMID: 24292660 DOI: 10.1172/JCI70678] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 120 |
Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochem Biophys Res Commun. 2014;443:278-284. [PMID: 24309097 DOI: 10.1016/j.bbrc.2013.11.104] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 121 |
Reuss B. Antibodies directed to Neisseria gonorrhoeae impair nerve growth factor-dependent neurite outgrowth in Rat PC12 cells. J Mol Neurosci 2014;52:353-65. [PMID: 24203572 DOI: 10.1007/s12031-013-0156-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 122 |
Staton DM, Solomon PR. Microinjections of d-amphetamine into the nucleus accumbens and caudate-putamen differentially affect stereotypy and locomotion in the rat. Psychobiology 1984;12:159-62. [DOI: 10.3758/bf03332184] [Cited by in Crossref: 122] [Cited by in F6Publishing: 122] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 123 |
Reichelt AC, Good MA, Killcross S. Attenuation of acute d-amphetamine-induced disruption of conflict resolution by clozapine, but not α-flupenthixol in rats. J Psychopharmacol 2013;27:1023-31. [PMID: 24043725 DOI: 10.1177/0269881113503503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 124 |
Gil-da-Costa R, Stoner GR, Fung R, Albright TD. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc Natl Acad Sci U S A 2013;110:15425-30. [PMID: 23959894 DOI: 10.1073/pnas.1312264110] [Cited by in Crossref: 111] [Cited by in F6Publishing: 121] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 125 |
Wenthur CJ, Lindsley CW. Classics in chemical neuroscience: clozapine. ACS Chem Neurosci 2013;4:1018-25. [PMID: 24047509 DOI: 10.1021/cn400121z] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 126 |
Trotman HD, Holtzman CW, Ryan AT, Shapiro DI, MacDonald AN, Goulding SM, Brasfield JL, Walker EF. The development of psychotic disorders in adolescence: a potential role for hormones. Horm Behav 2013;64:411-9. [PMID: 23998682 DOI: 10.1016/j.yhbeh.2013.02.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 127 |
Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Everall IP. Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci 2013;7:95. [PMID: 23805071 DOI: 10.3389/fncel.2013.00095] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 128 |
Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013;27:327-36. [PMID: 23413275 DOI: 10.1177/0269881113477709] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 129 |
Guest PC, Martins-de-Souza D, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med 2013;5:25. [PMID: 23531373 DOI: 10.1186/gm429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 130 |
Ocklenburg S, Arning L, Gerding WM, Epplen JT, Güntürkün O, Beste C. Cholecystokinin A receptor (CCKAR) gene variation is associated with language lateralization. PLoS One 2013;8:e53643. [PMID: 23341962 DOI: 10.1371/journal.pone.0053643] [Cited by in Crossref: 30] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 131 |
Lakhan SE, Caro M, Hadzimichalis N. NMDA Receptor Activity in Neuropsychiatric Disorders. Front Psychiatry 2013;4:52. [PMID: 23772215 DOI: 10.3389/fpsyt.2013.00052] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 132 |
Mcarthur RA. Preface. Translational Neuroimaging 2013. [DOI: 10.1016/b978-0-12-386945-6.05001-0] [Reference Citation Analysis]
|
| 133 |
Orenes I, Navarrete G, Beltrán D, Santamaría C. Schizotypal people stick longer to their first choices. Psychiatry Res 2012;200:620-8. [PMID: 22521898 DOI: 10.1016/j.psychres.2012.03.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 134 |
McCullumsmith RE, Hammond J, Funk A, Meador-Woodruff JH. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Curr Pharm Biotechnol 2012;13:1535-42. [PMID: 22283761 DOI: 10.2174/138920112800784899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 135 |
Gottschalk MG, Sarnyai Z, Guest PC, Harris LW, Bahn S. Estudos traducionais de neuropsiquiatria e esquizofrenia: modelos animais genéticos e de neurodesenvolvimento. Arch Clin Psychiatry (São Paulo) 2013;40:41-50. [DOI: 10.1590/s0101-60832012005000007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 136 |
Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 2012;3:195. [PMID: 23189055 DOI: 10.3389/fphar.2012.00195] [Cited by in Crossref: 109] [Cited by in F6Publishing: 117] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 137 |
Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE. Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. Bioorg Med Chem 2012;20:6366-74. [PMID: 23018094 DOI: 10.1016/j.bmc.2012.08.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 138 |
Maia-de-oliveira JP, Trzesniak C, Oliveira IR, Kempton MJ, Rezende TMND, Iego S, Baker GB, Dursun SM, Machado-de-sousa JP, Hallak JE. Nitric Oxide Plasma/Serum Levels In Patients With Schizophrenia: A Systematic Review And Meta-Analysis. Revista Brasileira de Psiquiatria 2012;34:149-62. [DOI: 10.1016/j.rbp.2012.07.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 139 |
Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, Ohno Y. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:252-9. [PMID: 22542492 DOI: 10.1016/j.pnpbp.2012.04.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 140 |
Panther P, Nullmeier S, Dobrowolny H, Schwegler H, Wolf R. CPB-K mice a mouse model of schizophrenia? Differences in dopaminergic, serotonergic and behavioral markers compared to BALB/cJ mice. Behav Brain Res 2012;230:215-28. [PMID: 22454846 DOI: 10.1016/j.bbr.2012.02.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 141 |
Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology 2013;64:254-63. [PMID: 22824189 DOI: 10.1016/j.neuropharm.2012.07.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 142 |
Dichter GS, Damiano CA, Allen JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord 2012;4:19. [PMID: 22958744 DOI: 10.1186/1866-1955-4-19] [Cited by in Crossref: 181] [Cited by in F6Publishing: 202] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 143 |
Perogamvros L, Schwartz S. The roles of the reward system in sleep and dreaming. Neurosci Biobehav Rev 2012;36:1934-51. [PMID: 22669078 DOI: 10.1016/j.neubiorev.2012.05.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 145] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 144 |
Tsou JY. Intervention, causal reasoning, and the neurobiology of mental disorders: Pharmacological drugs as experimental instruments. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 2012;43:542-51. [DOI: 10.1016/j.shpsc.2012.01.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 145 |
Essali A, Ali G. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2012;:CD004162. [PMID: 22336800 DOI: 10.1002/14651858.CD004162.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 146 |
Kendler KS. Levels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology. Mol Psychiatry 2012;17:11-21. [PMID: 21670729 DOI: 10.1038/mp.2011.70] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 147 |
Meltzer HY. Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics. Current Antipsychotics 2012. [DOI: 10.1007/978-3-642-25761-2_4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 148 |
Cueva JP, Chemel BR, Juncosa JI Jr, Lill MA, Watts VJ, Nichols DE. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. Eur J Med Chem 2012;48:97-107. [PMID: 22204903 DOI: 10.1016/j.ejmech.2011.11.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 149 |
Torvinen M, Kalenius E, Sansone F, Casnati A, Jänis J. Noncovalent Complexation of Monoamine Neurotransmitters and Related Ammonium Ions by Tetramethoxy Tetraglucosylcalix[4]arene. J Am Soc Mass Spectrom 2012;23:359-65. [DOI: 10.1007/s13361-011-0289-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 150 |
Alcaro A, Panksepp J. The SEEKING mind: Primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Neuroscience & Biobehavioral Reviews 2011;35:1805-20. [DOI: 10.1016/j.neubiorev.2011.03.002] [Cited by in Crossref: 137] [Cited by in F6Publishing: 121] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 151 |
Barak S, Weiner I. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol 2011;14:1233-46. [PMID: 21211109 DOI: 10.1017/S1461145710001549] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 152 |
Clark AH, McCorvy JD, Watts VJ, Nichols DE. Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorg Med Chem 2011;19:5420-31. [PMID: 21862338 DOI: 10.1016/j.bmc.2011.07.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 153 |
Belardetti F. Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse. Future Med Chem 2010;2:791-802. [PMID: 21426203 DOI: 10.4155/fmc.10.30] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 154 |
Fantino E, Stolarz-fantino S. Rational analysis and illogical inference. Behav Brain Sci 1991;14:494-494. [DOI: 10.1017/s0140525x00070904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 155 |
Anderson JR. Is human cognition adaptive? Behav Brain Sci 1991;14:471-85. [DOI: 10.1017/s0140525x00070801] [Cited by in Crossref: 192] [Cited by in F6Publishing: 197] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 156 |
Campbell RL, Bickhard MH. If human cognition is adaptive, can human knowledge consist of encodings? Behav Brain Sci 1991;14:488-9. [DOI: 10.1017/s0140525x00070849] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 157 |
Baron J. Some thinking is irrational. Behav Brain Sci 1991;14:486-7. [DOI: 10.1017/s0140525x00070825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 158 |
Anderson JR. More on rational analysis. Behav Brain Sci 1991;14:508-17. [DOI: 10.1017/s0140525x00071077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 159 |
de Sousa R. Rational analysis: Too rational for comfort? Behav Brain Sci 1991;14:492-492. [DOI: 10.1017/s0140525x00070874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 160 |
Tsotsos JK. Computational resources do constrain behavior. Behav Brain Sci 1991;14:506-7. [DOI: 10.1017/s0140525x00071053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 161 |
Sherin JE, Marder SR. Pharmacological Treatment. Schizophrenia 2011. [DOI: 10.1002/9780470978672.ch6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 162 |
Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11:59-67. [PMID: 21420906 DOI: 10.1016/j.coph.2011.02.007] [Cited by in Crossref: 249] [Cited by in F6Publishing: 259] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 163 |
Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother 2010;10:1637-58. [PMID: 20977322 DOI: 10.1586/ern.10.143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 164 |
Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011;213:289-305. [PMID: 21212939 DOI: 10.1007/s00213-010-2137-8] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 165 |
Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 2011;45:140-7. [PMID: 21091263 DOI: 10.3109/00048674.2010.533364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 166 |
Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012;62:1574-83. [PMID: 21277876 DOI: 10.1016/j.neuropharm.2011.01.022] [Cited by in Crossref: 329] [Cited by in F6Publishing: 360] [Article Influence: 27.4] [Reference Citation Analysis]
|
| 167 |
Nullmeier S, Panther P, Dobrowolny H, Frotscher M, Zhao S, Schwegler H, Wolf R. Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice. Eur J Neurosci 2011;33:689-98. [PMID: 21226776 DOI: 10.1111/j.1460-9568.2010.07563.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 168 |
Rehfeld JF. Cholecystokinin. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 337-58. [DOI: 10.1002/cphy.cp060216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 169 |
Meltzer HY, Sun L, Hashimoto H. The 5-HT2C Receptor as a Target for Schizophrenia. 5-HT2C Receptors in the Pathophysiology of CNS Disease 2011. [DOI: 10.1007/978-1-60761-941-3_14] [Reference Citation Analysis]
|
| 170 |
Sarnyai Z, Alsaif M, Bahn S, Ernst A, Guest PC, Hradetzky E, Kluge W, Stelzhammer V, Wesseling H. Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders. Int Rev Neurobiol 2011;101:203-38. [PMID: 22050853 DOI: 10.1016/B978-0-12-387718-5.00008-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 171 |
Geldenhuys WJ, Kuzenko SR, Simmons MA. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem 2010;53:8080-8. [PMID: 21047106 DOI: 10.1021/jm1010012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 172 |
Valenti O, Grace AA. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Int J Neuropsychopharmacol 2010;13:845-60. [PMID: 19751544 DOI: 10.1017/S1461145709990599] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 173 |
Weiner I. What the brain teaches us about latent inhibition (LI): the neural substrates of the expression and prevention of LI. Latent Inhibition 2010. [DOI: 10.1017/cbo9780511730184.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 174 |
Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010;11:256-61. [PMID: 20218790 DOI: 10.3109/15622970802309617] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 175 |
Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-92. [PMID: 19907417 DOI: 10.1038/npp.2009.176] [Cited by in Crossref: 205] [Cited by in F6Publishing: 210] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 176 |
Capuano B, Crosby IT, Forsyth CM, Mcrobb FM, Moudretski VV, Taylor DA, Vom A, Yuriev E. New hybrids of clozapine and haloperidol and their isosteric analogues: synthesis, X-ray crystallography, conformational analysis and preliminary pharmacological evaluation. Struct Chem 2010;21:613-28. [DOI: 10.1007/s11224-010-9591-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 177 |
Anisman H. Anhedonia: Too much, too soon. Behav Brain Sci 1982;5:53-4. [DOI: 10.1017/s0140525x00010384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 178 |
Beninger RJ. The behavioral function of dopamine. Behav Brain Sci 1982;5:55-6. [DOI: 10.1017/s0140525x00010402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 179 |
Neill D. Problems of concept and vocabulary in the anhedonia hypothesis. Behav Brain Sci 1982;5:70-70. [DOI: 10.1017/s0140525x00010542] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 180 |
Soubrie P. Neuroleptic-induced anhedonia: Some psychopharmacological implications. Behav Brain Sci 1982;5:76-7. [DOI: 10.1017/s0140525x00010608] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 181 |
Koob GF. The dopamine anhedonia hypothesis: A pharmacological phrenology. Behav Brain Sci 1982;5:63-4. [DOI: 10.1017/s0140525x00010475] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 182 |
Nemeroff CB, Luttinger D. The anhedonia hypothesis of neuroleptic drug action: Basic and clinical considerations. Behav Brain Sci 1982;5:70-1. [DOI: 10.1017/s0140525x00010554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 183 |
Arbuthnott GW. Support for the hypothesis that the actions of dopamine are “not merely motor.”. Behav Brain Sci 1982;5:54-5. [DOI: 10.1017/s0140525x00010396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 184 |
Wise RA. Hypotheses of neuroleptic action: Levels of progress. Behav Brain Sci 1982;5:78-87. [DOI: 10.1017/s0140525x00010621] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 185 |
Solomon PR, Crider A. Attention, dopamine, and schizophrenia. Behav Brain Sci 1982;5:75-6. [DOI: 10.1017/s0140525x00010591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 186 |
Panksepp J. The pleasure in brain substrates of foraging. Behav Brain Sci 1982;5:71-2. [DOI: 10.1017/s0140525x00010566] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 187 |
Sinnamon HM. The reward-effort model: An economic framework for examining the mechanism of neuroleptic action. Behav Brain Sci 1982;5:73-5. [DOI: 10.1017/s0140525x0001058x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 188 |
Rech RH. Neurolepsis: Anhedonia or blunting of emotional reactivity? Behav Brain Sci 1982;5:72-3. [DOI: 10.1017/s0140525x00010578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 189 |
Katz RJ. Dopamine and the limits of behavioral reduction – or why aren't all schizophrenics fat and happy? Behav Brain Sci 1982;5:60-1. [DOI: 10.1017/s0140525x00010451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 190 |
Wise RA. Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci 1982;5:39-53. [DOI: 10.1017/s0140525x00010372] [Cited by in Crossref: 781] [Cited by in F6Publishing: 783] [Article Influence: 60.1] [Reference Citation Analysis]
|
| 191 |
Ettenberg A. Behavioral effects of neuroleptics: Performance deficits, reward deficits or both? Behav Brain Sci 1982;5:56-7. [DOI: 10.1017/s0140525x00010414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Milgram NW. On the generality of the anhedonia hypothesis. Behav Brain Sci 1982;5:69-69. [DOI: 10.1017/s0140525x00010530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 193 |
German DC. Dopamine neurons, reward and behavior. Behav Brain Sci 1982;5:59-60. [DOI: 10.1017/s0140525x00010438] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 194 |
Liebman J. Understanding neuroleptics: From “anhedonia” to “neuroleptothesia”. Behav Brain Sci 1982;5:64-5. [DOI: 10.1017/s0140525x00010487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 195 |
Malmo RB, Malmo HP. Wise's neural model implicating the reticular formation: Some queries. Behav Brain Sci 1982;5:66-7. [DOI: 10.1017/s0140525x00010517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 196 |
Freed WJ, Zec RF. Criteria for ruling out sedation as an interpretation of neuroleptic effects. Behav Brain Sci 1982;5:57-9. [DOI: 10.1017/s0140525x00010426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 197 |
Gotoh L, Mitsuyasu H, Kobayashi Y, Oribe N, Takata A, Ninomiya H, Stanton VP Jr, Springett GM, Kawasaki H, Kanba S. Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatr Genet 2009;19:328-35. [PMID: 19820430 DOI: 10.1097/YPG.0b013e3283328e26] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 198 |
Quednow BB, Geyer MA, Halberstadt AL. Serotonin and Schizophrenia. Handbook of the Behavioral Neurobiology of Serotonin. Elsevier; 2010. pp. 585-620. [DOI: 10.1016/s1569-7339(10)70102-8] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 199 |
Meyer U, Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009;206:587-602. [PMID: 19277608 DOI: 10.1007/s00213-009-1504-9] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 200 |
Mcfarland K. Motor Control: Pyramidal, Extrapyramidal, and Limbic Motor Control. Handbook of Neuroscience for the Behavioral Sciences 2009. [DOI: 10.1002/9780470478509.neubb001023] [Reference Citation Analysis]
|
| 201 |
Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol 2009;623:73-83. [PMID: 19765575 DOI: 10.1016/j.ejphar.2009.09.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 202 |
Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry 2009;17:214-25. [PMID: 19499420 DOI: 10.1080/10673220902979896] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 203 |
Belli S. A psychobiographical analysis of Brian Douglas Wilson: Creativity, drugs, and models of schizophrenic and affective disorders. Personality and Individual Differences 2009;46:809-19. [DOI: 10.1016/j.paid.2009.01.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 204 |
Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) 2009;202:259-73. [PMID: 18766331 DOI: 10.1007/s00213-008-1302-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 205 |
Wolf JA, Moyer JT, Finkel LH. The Effects of Dopaminergic Modulation on Afferent Input Integration in the Ventral Striatal Medium Spiny Neuron. Advances in Behavioral Biology 2009. [DOI: 10.1007/978-1-4419-0340-2_14] [Reference Citation Analysis]
|
| 206 |
Li K, Xue B, Wang Y, Wang X, Wang H, Wang X. Ventral mesencephalon astrocytes are more efficient than those of other regions in inducing dopaminergic neurons through higher expression level of TGF-beta3. J Mol Neurosci 2009;37:288-300. [PMID: 18982456 DOI: 10.1007/s12031-008-9146-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 207 |
Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008;8:1037-48. [PMID: 18590475 DOI: 10.1586/14737175.8.7.1037] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 208 |
Perrone-bizzozero NI, Bullock WM. Schizophrenia: Biological Mechanisms. Wiley Encyclopedia of Chemical Biology 2008. [DOI: 10.1002/9780470048672.wecb669] [Reference Citation Analysis]
|
| 209 |
Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, Takahashi N, Maeno N, Kawasaki Y, Zhou SY, Hagino H, Niu L, Tsuneki H, Kobayashi S, Sasaoka T, Seto H, Kurachi M, Ozaki N. The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesio interthalamica and medial temporal lobe structures. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1236-42. [PMID: 18472202 DOI: 10.1016/j.pnpbp.2008.03.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 210 |
Gebhardt S, Grant P, von Georgi R, Huber MT. Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders - an integrative model. Med Hypotheses 2008;71:426-33. [PMID: 18524496 DOI: 10.1016/j.mehy.2008.03.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 211 |
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007;51:s13-8. [PMID: 18055930 DOI: 10.1192/bjp.191.51.s13] [Cited by in Crossref: 86] [Cited by in F6Publishing: 102] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 212 |
Weiser M, Reichenberg A, Werbeloff N, Kravitz E, Halperin D, Lubin G, Shmushkevitch M, Yoffe R, Addington J, Davidson M. Self-report of family functioning and risk for psychotic disorders in male adolescents with behavioural disturbances. Acta Psychiatr Scand 2008;117:225-31. [PMID: 18241305 DOI: 10.1111/j.1600-0447.2007.01143.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 213 |
Healy D. The Intersection of Psychopharmacology and Psychiatry in the Second Half of the Twentieth Century. In: Wallace ER, Gach J, editors. History of Psychiatry and Medical Psychology. Boston: Springer US; 2008. pp. 419-37. [DOI: 10.1007/978-0-387-34708-0_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 214 |
. The australian psychological society 13th annual conference. Australian Psychologist 1978;13:257-93. [DOI: 10.1080/00050067808254319] [Reference Citation Analysis]
|
| 215 |
Wolf R, Paelchen K, Matzke K, Dobrowolny H, Bogerts B, Schwegler H. Acute or subchronic clozapine treatment does not ameliorate prepulse inhibition (PPI) deficits in CPB-K mice with low levels of hippocampal NMDA receptor density. Psychopharmacology (Berl) 2007;194:93-102. [PMID: 17541558 DOI: 10.1007/s00213-007-0824-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 216 |
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. [PMID: 17641146 DOI: 10.1093/schbul/sbm083] [Cited by in Crossref: 142] [Cited by in F6Publishing: 147] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 217 |
Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007;56:283-321. [PMID: 17905440 DOI: 10.1016/j.brainresrev.2007.07.014] [Cited by in Crossref: 299] [Cited by in F6Publishing: 242] [Article Influence: 18.7] [Reference Citation Analysis]
|
| 218 |
Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 2007;21:620-7. [PMID: 17092971 DOI: 10.1177/0269881106072090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 219 |
Moore SC, Sellen JL. Jumping to conclusions: a network model predicts schizophrenic patients' performance on a probabilistic reasoning task. Cogn Affect Behav Neurosci 2006;6:261-9. [PMID: 17458441 DOI: 10.3758/cabn.6.4.261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 220 |
Tuckwell HC. On reaction dynamics at dopamine synapses. Int J Neurosci 2007;117:667-79. [PMID: 17464784 DOI: 10.1080/00207450600773905] [Reference Citation Analysis]
|
| 221 |
Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 2007;12:265-8. [PMID: 17426663 DOI: 10.1017/s1092852900021015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 222 |
Meltzer HY. Atypical Antipsychotic Drugs: Mechanism of Action. Handbook of Contemporary Neuropharmacology 2007. [DOI: 10.1002/9780470101001.hcn034] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 223 |
Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24. [PMID: 17242588 DOI: 10.1097/00131746-200701000-00003] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 224 |
Hibino H, Tochigi M, Otowa T, Kato N, Sasaki T. No association of DRD2, DRD3, and tyrosine hydroxylase gene polymorphisms with personality traits in the Japanese population. Behav Brain Funct 2006;2:32. [PMID: 17018139 DOI: 10.1186/1744-9081-2-32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 225 |
Levant B, Ozias MK, Carlson SE. Sex-specific effects of brain LC-PUFA composition on locomotor activity in rats. Physiology & Behavior 2006;89:196-204. [DOI: 10.1016/j.physbeh.2006.06.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 226 |
De Jesus OT, Van Hoffaert GJ, Glock D, Goldber LI, Friedman AH. Synthesis of a radiobrominated analog of SCH 23390, a selfctive dopamine D1/DA1 antagonist. J Label Compd Radiopharm 1986;23:919-25. [DOI: 10.1002/jlcr.2580230902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 227 |
Peleg-Raibstein D, Feldon J. Effects of dorsal and ventral hippocampal NMDA stimulation on nucleus accumbens core and shell dopamine release. Neuropharmacology 2006;51:947-57. [PMID: 16876207 DOI: 10.1016/j.neuropharm.2006.06.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 228 |
Guitart X, Codony X, Ballarín M, Dordal A, Farré AJ. E-5842: A New Potent and Preferential Sigma Ligand. Preclinical Pharmacological Profile. CNS Drug Reviews 1998;4:201-24. [DOI: 10.1111/j.1527-3458.1998.tb00065.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 229 |
Spooren W, Riemer C, Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005;4:967-75. [PMID: 16341062 DOI: 10.1038/nrd1905] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 230 |
Sanislow CA, Carson RC. Schizophrenia: A Critical Examination. Comprehensive Handbook of Psychopathology. [DOI: 10.1007/0-306-47377-1_15] [Reference Citation Analysis]
|
| 231 |
Tochigi M, Otowa T, Hibino H, Kato C, Otani T, Umekage T, Utsumi T, Kato N, Sasaki T. Combined analysis of association between personality traits and three functional polymorphisms in the tyrosine hydroxylase, monoamine oxidase A, and catechol-O-methyltransferase genes. Neurosci Res 2006;54:180-5. [PMID: 16360899 DOI: 10.1016/j.neures.2005.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 75] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 232 |
Brennan MD, Condra J. Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005;139B:69-72. [PMID: 16152568 DOI: 10.1002/ajmg.b.30222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 233 |
Tejedor-Real P, Vogel R, Mallet J, Biguet NF. Gi/Go protein-dependent presynaptic mechanisms are involved in clozapine-induced down-regulation of tyrosine hydroxylase in PC12 cells. J Neurosci Res 2005;81:739-45. [PMID: 15983997 DOI: 10.1002/jnr.20585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 234 |
Torres-hernández AR, González-vegas JA. Effects of 17β-estradiol on the spontaneous activity of substantia nigra neurons: Evidence for a non-genomic mechanism. Brain Research 2005;1049:1-7. [DOI: 10.1016/j.brainres.2005.04.085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 235 |
Carlson KM, Wagner GC. Effects of phencyclidine on schedule-controlled responding following neurotoxic lesions of the striatum. Life Sciences 2005;77:372-85. [DOI: 10.1016/j.lfs.2004.08.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 236 |
Sundram S, Dean B, Copolov D. The endogenous cannabinoid system in schizophrenia. Marijuana and Madness 2004. [DOI: 10.1017/cbo9780511543630.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 237 |
Minabe Y, Shirayama Y, Hashimoto K, Routledge C, Hagan JJ, Ashby CR. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 2004;52:20-8. [DOI: 10.1002/syn.20002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 238 |
Lenzi A, Tuscano D. Do Acetylcholinesterase Inhibitors Have a Role in Improving Cognitive Impairment in Patients with Schizophrenia?: . International Journal of Pharmaceutical Medicine 2004;18:139-48. [DOI: 10.2165/00124363-200418030-00002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 239 |
Smidt MP, Smits SM, Burbach JH. Molecular mechanisms underlying midbrain dopamine neuron development and function. European Journal of Pharmacology 2003;480:75-88. [DOI: 10.1016/j.ejphar.2003.08.094] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 240 |
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72. [PMID: 14642974 DOI: 10.1016/j.pnpbp.2003.09.010] [Cited by in Crossref: 578] [Cited by in F6Publishing: 590] [Article Influence: 28.9] [Reference Citation Analysis]
|
| 241 |
Meltzer H. Multiple neurotransmitters involved in antipsychotic drug action. Dopamine in the Pathophysiology and Treatment of Schizophrenia 2003. [DOI: 10.3109/9780203427347-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 242 |
Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 2003;169:257-97. [PMID: 12601500 DOI: 10.1007/s00213-002-1313-x] [Cited by in Crossref: 320] [Cited by in F6Publishing: 321] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 243 |
Csernansky JG. Treatment of schizophrenia: preventing the progression of disease. Psychiatr Clin North Am 2003;26:367-79. [PMID: 12778839 DOI: 10.1016/s0193-953x(02)00113-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 244 |
Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003;28:839-49. [PMID: 12637956 DOI: 10.1038/sj.npp.1300114] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 245 |
Dean B, Bradbury R, Copolov DL. Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol Psychiatry 2003;53:585-92. [PMID: 12679236 DOI: 10.1016/s0006-3223(02)01545-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 246 |
Tejedor-Real P, Faucon Biguet N, Dumas S, Mallet J. Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostriatal systems. J Neurosci Res 2003;72:105-15. [PMID: 12645084 DOI: 10.1002/jnr.10555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 247 |
Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL. Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology (Berl) 2003;167:79-84. [PMID: 12632247 DOI: 10.1007/s00213-002-1381-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 248 |
Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003;97:153-79. [PMID: 12559388 DOI: 10.1016/s0163-7258(02)00328-5] [Cited by in Crossref: 236] [Cited by in F6Publishing: 240] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 249 |
Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002;958:176-84. [PMID: 12468043 DOI: 10.1016/s0006-8993(02)03692-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 250 |
Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 2002;46:129-39. [PMID: 12325040 DOI: 10.1002/syn.10116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 251 |
Cochran S, Mckerchar C, Morris B, Pratt J. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology 2002;43:394-407. [DOI: 10.1016/s0028-3908(02)00091-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 252 |
Liégeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002;947:157-65. [PMID: 12176156 DOI: 10.1016/s0006-8993(02)02620-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 253 |
Sommer BR, Wise LC, Kraemer HC. Is dopamine administration possibly a risk factor for delirium? Crit Care Med 2002;30:1508-11. [PMID: 12130971 DOI: 10.1097/00003246-200207000-00019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 254 |
Angelopoulos EK, Markianos M, Daskalopoulou EG, Hatzimanolis J, Tzemos J. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Res 2002;110:9-17. [PMID: 12007589 DOI: 10.1016/s0165-1781(02)00037-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 255 |
Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002;41:538-45. [PMID: 12014786 DOI: 10.1097/00004583-200205000-00011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 256 |
Gracey DJ, Bell R, King DJ. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:497-504. [PMID: 11999900 DOI: 10.1016/s0278-5846(01)00296-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 257 |
Mewshaw RE, Zhao R, Shi X, Marquis K, Brennan JA, Mazandarani H, Coupet J, Andree TH. New generation dopaminergic agents. Part 8: heterocyclic bioisosteres that exploit the 7-OH-2-(aminomethyl)chroman D(2) template. Bioorg Med Chem Lett 2002;12:271-4. [PMID: 11814775 DOI: 10.1016/s0960-894x(01)00778-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 258 |
Weiner I, Joel D. Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits. Dopamine in the CNS II 2002. [DOI: 10.1007/978-3-662-06765-9_13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 259 |
Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 2000;20:8987-95. [PMID: 11124974 [PMID: 11124974 DOI: 10.1523/jneurosci.20-24-08987.2000] [Cited by in Crossref: 357] [Cited by in F6Publishing: 360] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 260 |
Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci U S A 2001;98:1964-9. [PMID: 11172059 DOI: 10.1073/pnas.98.4.1964] [Cited by in Crossref: 116] [Cited by in F6Publishing: 130] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 261 |
Rodríguez JJ, Garcia DR, Nakabeppu Y, Pickel VM. FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse 2001;39:122-32. [PMID: 11180499 DOI: 10.1002/1098-2396(200102)39:2<122::AID-SYN3>3.0.CO;2-R] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 262 |
Warner R. Schizophrenia. International Encyclopedia of the Social & Behavioral Sciences 2001. [DOI: 10.1016/b0-08-043076-7/04749-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 263 |
Salgado JV, Vidal M, Oberling P, Graeff FG, Danion JM, Sandner G. Associative learning and latent inhibition in a conditioned suppression paradigm in humans. Behav Brain Res 2000;117:53-60. [PMID: 11099757 DOI: 10.1016/s0166-4328(00)00280-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 264 |
Salgado JV, Hetem LA, Vidal M, Graeff FG, Danion JM, Sandner G. Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans. Behav Brain Res 2000;117:61-7. [PMID: 11099758 DOI: 10.1016/s0166-4328(00)00279-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 265 |
Huberman A, Turek VF, Carlisle HJ. Clozapine does not induce a motor impairment in operant responding for heat reinforcement. Pharmacol Biochem Behav 2000;67:307-12. [PMID: 11124394 DOI: 10.1016/s0091-3057(00)00364-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 266 |
Burbach JP. Genetic pathways in the developmental specification of hypothalamic neuropeptide and midbrain catecholamine systems. Eur J Pharmacol 2000;405:55-62. [PMID: 11033314 DOI: 10.1016/s0014-2999(00)00541-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 267 |
Bujas-Bobanovic M, Bird DC, Robertson HA, Dursun SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 2000;130:1005-12. [PMID: 10882384 DOI: 10.1038/sj.bjp.0703406] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 268 |
Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects. Neuropharmacology 2000;39:1211-21. [PMID: 10760363 DOI: 10.1016/s0028-3908(99)00214-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 269 |
Ding YS, Logan J, Bermel R, Garza V, Rice O, Fowler JS, Volkow ND. Dopamine receptor-mediated regulation of striatal cholinergic activity: positron emission tomography studies with norchloro[18F]fluoroepibatidine. J Neurochem 2000;74:1514-21. [PMID: 10737608 DOI: 10.1046/j.1471-4159.2000.0741514.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 270 |
Den Boer JA, Vahlne JO, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum Psychopharmacol 2000;15:179-89. [PMID: 12404331 DOI: 10.1002/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 271 |
Procyshyn RM, Kennedy NB. Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders: . Clinical Drug Investigation 2000;19:257-66. [DOI: 10.2165/00044011-200019040-00003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 272 |
Ichikawa J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 2000;858:252-63. [PMID: 10708676 DOI: 10.1016/s0006-8993(99)02346-x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 273 |
Gracey DJ, Bell R, King DJ. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat. Pharmacol Biochem Behav 2000;65:459-63. [PMID: 10683486 DOI: 10.1016/s0091-3057(99)00227-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 274 |
Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D. Screening of antipsychotic drugs in animal models. Drug Dev Res 2000;50:235-49. [DOI: 10.1002/1098-2299(200007/08)50:3/4<235::aid-ddr7>3.0.co;2-r] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 275 |
Meltzer HY. Multireceptor atypical antipsychotic drugs. In: Ellenbroek BA, Cools AR, editors. Atypical Antipsychotics. Basel: Birkhäuser; 2000. pp. 191-213. [DOI: 10.1007/978-3-0348-8448-8_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 276 |
Weiner I. The Latent Inhibition Model of Schizophrenia. Contemporary Issues in Modeling Psychopathology 2000. [DOI: 10.1007/978-1-4757-4860-4_12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 277 |
Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999;843:171-83. [PMID: 10528123 DOI: 10.1016/s0006-8993(99)01776-x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 278 |
Mewshaw RE, Nelson JA, Shah US, Shi X, Mazandarani H, Coupet J, Marquis K, Brennan JA, Andree TH. New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett 1999;9:2593-8. [PMID: 10498215 DOI: 10.1016/s0960-894x(99)00434-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 279 |
Hamelin BA, Dorson PG, Pabis D, Still D, Bouchard RH, Pourcher E, Rail J, Turgeon J, Crismon ML. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy 1999;19:1057-63. [PMID: 10610012 DOI: 10.1592/phco.19.13.1057.31593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 280 |
Gray JA, Kumari V, Lawrence N, Young AMJ. Functions of the dopaminergic innervation of the nucleus accumbens. Psychobiology 1999;27:225-235. [DOI: 10.3758/bf03332116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 281 |
Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999;29:250-64. [PMID: 10209235 DOI: 10.1016/s0165-0173(99)00002-8] [Cited by in Crossref: 128] [Cited by in F6Publishing: 133] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 282 |
Vysokanov A, Flores-Hernandez J, Surmeier DJ. mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons. Neurosci Lett 1998;258:179-82. [PMID: 9885960 DOI: 10.1016/s0304-3940(98)00882-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 283 |
Gioanni Y, Thierry AM, Glowinski J, Tassin JP. Alpha1-adrenergic, D1, and D2 receptors interactions in the prefrontal cortex: implications for the modality of action of different types of neuroleptics. Synapse 1998;30:362-70. [PMID: 9826228 DOI: 10.1002/(SICI)1098-2396(199812)30:4<362::AID-SYN3>3.0.CO;2-W] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 284 |
Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998;812:65-75. [PMID: 9813244 DOI: 10.1016/s0006-8993(98)00926-3] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 285 |
Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998;19:136-40. [PMID: 9612088 DOI: 10.1016/s0165-6147(98)01186-9] [Cited by in Crossref: 133] [Cited by in F6Publishing: 142] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 286 |
Gracey DJ, Bell R, King DJ, Trimble KM, McDermott BJ. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide. Pharmacol Biochem Behav 1998;59:1053-9. [PMID: 9586867 DOI: 10.1016/s0091-3057(97)00533-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 287 |
Sarre S, Smolders I, Thorré K, Ebinger G, Michotte Y. Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study. J Neural Transm (Vienna) 1997;104:1215-28. [PMID: 9503267 DOI: 10.1007/BF01294722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 288 |
Gray NS, Pickering AD, Gray JA, Jones SH, Abrahams S, Hemsley DR. Kamin blocking is not disrupted by amphetamine in human subjects. J Psychopharmacol 1997;11:301-11. [PMID: 9443517 DOI: 10.1177/026988119701100404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 289 |
Schmajuk N, Buhusi CV, Gray JA. The Transition from Automatic to Controlled Processing. Neural Netw 1997;10:1257-68. [PMID: 12662515 DOI: 10.1016/s0893-6080(97)00058-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 290 |
Varoqui H, Erickson JD. Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function. Mol Neurobiol 1997;15:165-91. [PMID: 9396009 DOI: 10.1007/BF02740633] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 291 |
Zhang X, Sun B, Jin G. Atypical neuroleptic properties ofl-stepholidine: Electrophysiological and behavioral studies. Sci China Ser C -Life Sci 1997;40:531-8. [DOI: 10.1007/bf03183593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 292 |
Fiorella D, Helsley S, Rabin RA, Winter JC. Further investigations of the interactions of antipsychotics with the (-)2,5-dimethoxy-4-methylamphetamine (DOM) discriminative stimulus. Neuropharmacology 1997;36:1463-9. [PMID: 9423935 DOI: 10.1016/s0028-3908(97)00121-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 293 |
Miller R. Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:1059-94. [PMID: 9421824 DOI: 10.1016/s0278-5846(97)00099-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 294 |
Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997;37:75-86. [PMID: 9285246 DOI: 10.1016/s0162-3109(97)00037-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 295 |
Wright JL, Gregory TF, Heffner TG, Mackenzie RG, Pugsley TA, Meulen SV, Wise LD. Discovery of selective dopamine D4 receptor antagonists: 1-Aryloxy-3-(4-aryloxypiperidinyl)-2-propanols. Bioorganic & Medicinal Chemistry Letters 1997;7:1377-80. [DOI: 10.1016/s0960-894x(97)00233-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 296 |
Baldessarini RJ. Dopamine Receptors and Clinical Medicine. The Dopamine Receptors 1997. [DOI: 10.1007/978-1-4757-2635-0_15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 297 |
Guterman Y, Josiassen RC, Bashore TE, Johnson M, Lubow RE. Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophr Res 1996;20:315-26. [PMID: 8827859 DOI: 10.1016/0920-9964(95)00086-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 298 |
Stelmack RM, Pivik R. Extraversion and the effect of exercise on spinal motoneuronal excitability. Personality and Individual Differences 1996;21:69-76. [DOI: 10.1016/0191-8869(96)00034-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 299 |
Lundberg T, Lindström L, Hartvig P, Reibring L, Agren H, Lundqvist H, Fasth KJ, Antoni G, Långström B. Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Res 1996;67:1-10. [PMID: 8797237 DOI: 10.1016/0925-4927(96)02653-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 300 |
White KE, Cummings JL. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry 1996;37:188-95. [PMID: 8732586 DOI: 10.1016/s0010-440x(96)90035-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 301 |
Ginsburg BE, Werick TM, Escobar JI, Kugelmass S, Treanor JJ, Wendtland L. Molecular genetics of psychopathologies: a search for simple answers to complex problems. Behav Genet 1996;26:325-33. [PMID: 8754255 DOI: 10.1007/BF02359388] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 302 |
Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindoleacetic acid in schizophrenia: a meta-analysis. Psychiatry Res 1996;59:239-44. [PMID: 8930029 DOI: 10.1016/0165-1781(95)02741-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 303 |
Megens AA, Kennis LE. Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent? Prog Med Chem 1996;33:185-232. [PMID: 8776944 DOI: 10.1016/s0079-6468(08)70306-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 304 |
Gaebel W, Wölwer W. Okulomotorik und dopaminerges System — Ein Funktionsmodell zur Analyse schizophrener Verhaltensstörungen. Aktuelle Perspektiven der Biologischen Psychiatrie 1996. [DOI: 10.1007/978-3-7091-6889-9_145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 305 |
Minabe Y, Emori K, Toor A, Stutzmann GE, Ashby CR Jr. The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: a single unit, extracellular recording study. Synapse 1996;22:35-45. [PMID: 8822476 DOI: 10.1002/(SICI)1098-2396(199601)22:1<35::AID-SYN4>3.0.CO;2-J] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 306 |
Ögren SO. The Behavioural Pharmacology of Typical and Atypical Antipsychotic Drugs. In: Csernansky JG, editor. Antipsychotics. Berlin: Springer Berlin Heidelberg; 1996. pp. 225-66. [DOI: 10.1007/978-3-642-61007-3_8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 307 |
Schlemmer RF Jr, Young JE, Davis JM. Stimulant-induced disruption of non-human primate social behavior and the psychopharmacology of schizophrenia. J Psychopharmacol 1996;10:64-76. [PMID: 22302729 DOI: 10.1177/026988119601000110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 308 |
Wright J, Downing D, Heffner T, Pugsley T, Mackenzie R, Wise L. Discovery of selective dopamine D3 ligands: I. Dimeric 2-[4-(3-aminopropoxy)phenyl]benzimidazole antagonists. Bioorganic & Medicinal Chemistry Letters 1995;5:2541-6. [DOI: 10.1016/0960-894x(95)00446-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 309 |
Gray JA, Joseph MH, Hemsley DR, Young AM, Warburton EC, Boulenguez P, Grigoryan GA, Peters SL, Rawlins JN, Taib CT. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 1995;71:19-31. [PMID: 8747172 DOI: 10.1016/0166-4328(95)00154-9] [Cited by in Crossref: 124] [Cited by in F6Publishing: 134] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 310 |
Fiorella D, Helsley S, Rabin RA, Winter JC. The interactions of typical and atypical antipsychotics with the (-)2, 5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus. Neuropharmacology 1995;34:1297-303. [PMID: 8570027 DOI: 10.1016/0028-3908(95)00101-b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 311 |
Lacroix D, Chaput Y, Rodriguez JP, Filion M, Morrison D, St-Denis P, Albert JM. Quantified EEG changes associated with a positive clinical response to clozapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:861-76. [PMID: 8539424 DOI: 10.1016/0278-5846(95)00116-d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 312 |
Wan W, Ennulat DJ, Cohen BM. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 1995;688:95-104. [PMID: 8542328 DOI: 10.1016/0006-8993(95)00544-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 313 |
Popoli P, Reggio R, Pèzzola A, Scotti de Carolis A. The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats. Psychopharmacology (Berl) 1995;120:156-61. [PMID: 7480547 DOI: 10.1007/BF02246188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 314 |
Tsai SJ, Huang YH, Chang LS, Yang YC, Sim CB. Alterations in local cerebral glucose utilization in rats after chronic amphetamine administration without subsequent challenge. Psychiatry Res 1995;57:65-73. [PMID: 7568560 DOI: 10.1016/0165-1781(95)02496-j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 315 |
Van Ree JM, Wolterink G, Igarashi Y, Vanderschuren L, Wiegant VM, Rust CJ, Bruning HW. Behavioral studies on the putative gamma-type endorphin receptor using different antibodies. Eur J Pharmacol 1995;279:187-96. [PMID: 7556400 DOI: 10.1016/0014-2999(95)00157-g] [Reference Citation Analysis]
|
| 316 |
Ereshefsky L. Treatment Strategies for Schizophrenia. Psychiatric Annals 1995;25:285-96. [DOI: 10.3928/0048-5713-19950501-08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 317 |
Benvenga MJ, Leander JD. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology (Berl) 1995;119:133-8. [PMID: 7544900 DOI: 10.1007/BF02246153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 318 |
Lambert GW, Horne M, Kalff V, Kelly MJ, Turner AG, Cox HS, Jennings GL, Esler MD. Central nervous system noradrenergic and dopaminergic turnover in response to acute neuroleptic challenge. Life Sci 1995;56:1545-55. [PMID: 7723582 DOI: 10.1016/0024-3205(95)00120-u] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 319 |
Meltzer HY. Psychotic Continuum or Distinct Entities: Perspective from Psychopharmacology. Psychotic Continuum 1995. [DOI: 10.1007/978-3-642-79485-8_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 320 |
Mcclure R, Keshavan M, Minshew NJ, Panchalingam K, Pettegrew JW. 31P Magnetic Resonance Spectroscopy Study of Brain Metabolism in Schizophrenia. Search for the Causes of Schizophrenia 1995. [DOI: 10.1007/978-3-642-79429-2_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 321 |
Ereshefsky L. Ein pharmakodynamisches und pathophysiologisches Modell der medikamentösen antipsychotischen Therapie der Schizophrenie. Schizophrenie 1995. [DOI: 10.1007/978-3-642-79738-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 322 |
Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994;91:11651-4. [PMID: 7972118 DOI: 10.1073/pnas.91.24.11651] [Cited by in Crossref: 254] [Cited by in F6Publishing: 265] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 323 |
Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 1994;384:95-101. [PMID: 7533472 DOI: 10.1111/j.1600-0447.1994.tb05897.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 324 |
Chen EY. A neural network model of cortical information processing in schizophrenia. I: Interaction between biological and social factors in symptom formation. Can J Psychiatry 1994;39:362-7. [PMID: 7834591 DOI: 10.1177/070674379403900803] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 325 |
Gray NS, Pickering AD, Gray JA. Psychoticism and dopamine D2 binding in the basal ganglia using single photon emission tomography. Personality and Individual Differences 1994;17:431-4. [DOI: 10.1016/0191-8869(94)90289-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 326 |
Palumbo PA, Winter JC. Interactions of clozapine with the stimulus effects of DOM and LSD. Pharmacol Biochem Behav 1994;49:115-20. [PMID: 7816860 DOI: 10.1016/0091-3057(94)90464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 327 |
Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994;36:230-6. [PMID: 7986887 DOI: 10.1016/0006-3223(94)90604-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 328 |
Radhakishun FS, Westerink BH, Stoof JC, Wolterink G, van Ree JM. Subchronic treatment with the neuroleptic-like peptide desenkephalin-gamma-endorphin may decrease dopaminergic neurotransmission in the nucleus accumbens of rats. Eur Neuropsychopharmacol 1994;4:127-36. [PMID: 7919942 DOI: 10.1016/0924-977x(94)90006-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 329 |
Maeda H. A theoretical and neurophysiological consideration on the pathogenesis of positive symptoms of schizophrenia: implications of dopaminergic function in the emotional circuit. Jpn J Psychiatry Neurol 1994;48:99-110. [PMID: 7933723 DOI: 10.1111/j.1440-1819.1994.tb03003.x] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 330 |
Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994;114:9-23. [PMID: 7531353 DOI: 10.1007/BF02245439] [Cited by in Crossref: 140] [Cited by in F6Publishing: 146] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 331 |
Koziol JA, Tuckwell HC. A Weighted Nonparametric Procedure for the Combination of Independent Events. Biom J 1994;36:1005-12. [DOI: 10.1002/bimj.4710360814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 332 |
Kessler A, Shinitzky M. Platelets from schizophrenic patients bear autoimmune antibodies that inhibit dopamine uptake. Psychobiology 1993;21:299-306. [DOI: 10.3758/bf03327149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 333 |
Thompson PA, Meltzer HY. Positive, negative, and disorganisation factors from the Schedule for Affective Disorders and Schizophrenia and the Present State Examination. A three-factor solution. Br J Psychiatry 1993;163:344-51. [PMID: 8401964 DOI: 10.1192/bjp.163.3.344] [Cited by in Crossref: 33] [Cited by in F6Publishing: 46] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 334 |
Rao ML, Gross G, Halaris A, Huber G, Marler M, Strebel B, Bräunig P. Hyperdopaminergia in schizophreniform psychosis: a chronobiological study. Psychiatry Res 1993;47:187-203. [PMID: 8341771 DOI: 10.1016/0165-1781(93)90048-l] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 335 |
Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993;13:350-6. [PMID: 8480281 DOI: 10.1002/syn.890130407] [Cited by in Crossref: 216] [Cited by in F6Publishing: 224] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 336 |
Jaén JC, Caprathe BW, Wise LD, Meltzer LT, Pugsley TA, Huffner TG. Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385. Bioorganic & Medicinal Chemistry Letters 1993;3:639-44. [DOI: 10.1016/s0960-894x(01)81245-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 337 |
Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993;46:139-49. [PMID: 8483973 DOI: 10.1016/0165-1781(93)90016-a] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 338 |
Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 1993;230:245-50. [PMID: 8095021 DOI: 10.1016/0014-2999(93)90557-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 339 |
Gaebel W. Die prädiktorische Bedeutung einer Neuroleptika-Testdosis. Therapieresistenz unter Neuroleptikabehandlung 1993. [DOI: 10.1007/978-3-7091-9292-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 340 |
Meltzer HY. Serotonin receptors and antipsychotic drug action. Psychopharmacol Ser 1993;10:70-81. [PMID: 8103227 DOI: 10.1007/978-3-642-78010-3_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 341 |
Megens AAHP. Die Pharmakologie von Risperidon. Brennpunkte der Schizophrenie 1993. [DOI: 10.1007/978-3-7091-9285-6_25] [Reference Citation Analysis]
|
| 342 |
Lambert GW, Eisenhofer G, Jennings GL, Esler MD. Regional homovanillic acid production in humans. Life Sci 1993;53:63-75. [PMID: 8515683 DOI: 10.1016/0024-3205(93)90612-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 343 |
Csernansky JG, Wrona CT, Bardgett ME, Early TS, Newcomer JW. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology (Berl) 1993;110:145-51. [PMID: 7870875 DOI: 10.1007/BF02246964] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 344 |
Mash DC, Zabetian CP. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 1992;12:195-205. [PMID: 1481139 DOI: 10.1002/syn.890120304] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 345 |
Merchant KM, Dobie DJ, Dorsa DM. Expression of the Proneurotensin Gene in the Rat Brain and Its Regulation by Antipsychotic Drugs. Ann NY Acad Sci 1992;668:54-69. [DOI: 10.1111/j.1749-6632.1992.tb27339.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 346 |
Kulkarni J, Horne M, Butler E, Keks N, Copolov D. Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease. Biol Psychiatry 1992;31:1225-7. [PMID: 1391283 DOI: 10.1016/0006-3223(92)90342-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 347 |
Meltzer HY, Zhang Y, Stockmeier CA. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol 1992;216:67-71. [PMID: 1388121 DOI: 10.1016/0014-2999(92)90210-u] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 348 |
Hurd YL, Lindefors N, Brodin E, Brene´ S, Persson H, Ungerstedt U, Ho¨kfelt T. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission. Brain Research 1992;578:317-26. [DOI: 10.1016/0006-8993(92)90264-a] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 349 |
Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 1992;31:560-70. [PMID: 1349833 DOI: 10.1016/0006-3223(92)90242-r] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 350 |
Barnes JM, Barnes NM, Cooper SJ. Behavioural pharmacology of 5-HT3 receptor ligands. Neurosci Biobehav Rev 1992;16:107-13. [PMID: 1553101 DOI: 10.1016/s0149-7634(05)80057-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 351 |
Cohen JD, Servan-schreiber D. A Neural Network Model of Disturbances in the Processing of Context in Schizophrenia. Psychiatric Annals 1992;22:131-6. [DOI: 10.3928/0048-5713-19920301-09] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 352 |
Kales A, Vgontzas AN. Advances in Biological Psychiatry. The Mosaic of Contemporary Psychiatry in Perspective 1992. [DOI: 10.1007/978-1-4613-9194-4_14] [Reference Citation Analysis]
|
| 353 |
Megens AAHP, Niemegeers CJE, Awouters FHL. Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 1992;26:129-45. [DOI: 10.1002/ddr.430260203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 354 |
Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl) 1992;107:425-30. [PMID: 1615140 DOI: 10.1007/BF02245170] [Cited by in Crossref: 220] [Cited by in F6Publishing: 215] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 355 |
Dethloff LA, de la Iglesia FA. Cholecystokinin antagonists--a toxicologic perspective. Drug Metab Rev 1992;24:267-93. [PMID: 1576938 DOI: 10.3109/03602539208996295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 356 |
Klimke A, Klieser E. Dopaminagonisten zur Schizophrenie-Behandlung: Ein neues therapeutisches Wirkprinzip? Biologische Psychiatrie 1992. [DOI: 10.1007/978-3-642-77086-9_48] [Reference Citation Analysis]
|
| 357 |
Heritch AJ. The Dopamine Hypothesis and Neurophysiology Concepts in Schizophrenia. Reviews in the Neurosciences 1992;3. [DOI: 10.1515/revneuro.1992.3.3.207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 358 |
Wiegant VM, Ronken E, Kovács G, De Wied D. Chapter 29 Endorphins and schizophrenia. The Human Hypothalamus in Health and Disease, Proceedings of the 17th International Summer School of Brain Research, held at the Auditorium of the University of Amsterdam. Elsevier; 1992. pp. 433-53. [DOI: 10.1016/s0079-6123(08)64588-4] [Cited by in Crossref: 19] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 359 |
Lynch MR. Schizophrenia and the D1 receptor: focus on negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:797-832. [PMID: 1355300 DOI: 10.1016/0278-5846(92)90102-k] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 360 |
Ereshefsky L, Richards AL. Psychoses. Applied Therapeutics 1992. [DOI: 10.1007/978-1-349-13175-4_56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 361 |
Karbe H, Wienhard K, Hamacher K, Huber M, Herholz K, Coenen HH, Stöcklin G, Lövenich A, Heiss WD. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991;86:163-73. [PMID: 1837996 DOI: 10.1007/BF01250702] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 362 |
Holyoak KJ. Probing the “Achilles' heel” of rational analysis. Behav Brain Sci 1991;14:498-499. [DOI: 10.1017/s0140525x00070965] [Reference Citation Analysis]
|
| 363 |
Agarwal GC. Human cognition is an adaptive process. Behav Brain Sci 1991;14:485-486. [DOI: 10.1017/s0140525x00070813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 364 |
Shafir E. On the nonapplicability of a rational analysis to human cognition. Behav Brain Sci 1991;14:502-503. [DOI: 10.1017/s0140525x00071004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 365 |
Gigerenzer G. Does the environment have the same structure as Bayes' theorem? Behav Brain Sci 1991;14:495-496. [DOI: 10.1017/s0140525x00070928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 19] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 366 |
Chandrasekaran B. Mechanistic and rationalistic explanations are complementary. Behav Brain Sci 1991;14:489-491. [DOI: 10.1017/s0140525x00070850] [Reference Citation Analysis]
|
| 367 |
Evans JSBT. Adaptive cognition: The question is how. Behav Brain Sci 1991;14:493-494. [DOI: 10.1017/s0140525x00070898] [Reference Citation Analysis]
|
| 368 |
Snow P. Rationality and irrationality: Still fighting words. Behav Brain Sci 1991;14:505-506. [DOI: 10.1017/s0140525x00071041] [Reference Citation Analysis]
|
| 369 |
Becker GM. The nonoptimality of Anderson's memory fits. Behav Brain Sci 1991;14:487-488. [DOI: 10.1017/s0140525x00070837] [Reference Citation Analysis]
|
| 370 |
Hastie R, Hammond KR. Rational analysis and the Lens model. Behav Brain Sci 1991;14:498-498. [DOI: 10.1017/s0140525x00070953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 371 |
Zétényi T. Human and nonhuman systems are adaptive in a different sense. Behav Brain Sci 1991;14:507-508. [DOI: 10.1017/s0140525x00071065] [Reference Citation Analysis]
|
| 372 |
Godfrey-smith P. Optimality and psychological explanation. Behav Brain Sci 1991;14:496-497. [DOI: 10.1017/s0140525x0007093x] [Reference Citation Analysis]
|
| 373 |
Smokler H. A Bayesian theory of thought. Behav Brain Sci 1991;14:505-505. [DOI: 10.1017/s0140525x0007103x] [Reference Citation Analysis]
|
| 374 |
Schwarz W. Rational analysis will not throw off the yoke of the precision-importance trade-off function. Behav Brain Sci 1991;14:501-502. [DOI: 10.1017/s0140525x00070990] [Reference Citation Analysis]
|
| 375 |
Geissler H. Beyond Helmholtz, or why not include inner determinants from the beginning? Behav Brain Sci 1991;14:494-495. [DOI: 10.1017/s0140525x00070916] [Reference Citation Analysis]
|
| 376 |
Shultz TR. The rationality of causal inference. Behav Brain Sci 1991;14:503-504. [DOI: 10.1017/s0140525x00071016] [Reference Citation Analysis]
|
| 377 |
Rivest R, Marsden CA. Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol. Br J Pharmacol 1991;104:234-8. [PMID: 1786513 DOI: 10.1111/j.1476-5381.1991.tb12412.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 378 |
Rachlin H. The cognitive laboratory, the library and the Skinner box. Behav Brain Sci 1991;14:501-501. [DOI: 10.1017/s0140525x00070989] [Reference Citation Analysis]
|
| 379 |
Dickinson BW. Adaptivity and rational analysis. Behav Brain Sci 1991;14:492-493. [DOI: 10.1017/s0140525x00070886] [Reference Citation Analysis]
|
| 380 |
Gregson RAM. Bayes in the context of suboptimality. Behav Brain Sci 1991;14:497-498. [DOI: 10.1017/s0140525x00070941] [Reference Citation Analysis]
|
| 381 |
Massaro DW, Friedman D. Adaptive rationality and identifiability of psychological processes. Behav Brain Sci 1991;14:499-501. [DOI: 10.1017/s0140525x00070977] [Reference Citation Analysis]
|
| 382 |
Corter JE. Normative theories of categorization. Behav Brain Sci 1991;14:491-492. [DOI: 10.1017/s0140525x00070862] [Reference Citation Analysis]
|
| 383 |
Small SL. But how does the brain think? (or wasn't that the question?). Behav Brain Sci 1991;14:504-505. [DOI: 10.1017/s0140525x00071028] [Reference Citation Analysis]
|
| 384 |
Csernansky JG, Murphy GM, Faustman WO. Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 1991;30:383-400. [PMID: 1912130 DOI: 10.1016/0006-3223(91)90295-w] [Cited by in Crossref: 91] [Cited by in F6Publishing: 90] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 385 |
Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-56. [PMID: 1674882 DOI: 10.1016/0920-9964(91)90030-u] [Cited by in Crossref: 168] [Cited by in F6Publishing: 161] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 386 |
Merchant KM, Miller MA, Ashleigh EA, Dorsa DM. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res 1991;540:311-4. [PMID: 2054626 DOI: 10.1016/0006-8993(91)90526-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 387 |
Bogerts B, Falkai P. Clinical and Neurodevelopmental Aspects of Brain Pathology in Schizophrenia. In: Mednick SA, Cannon TD, Barr CE, Lafosse JM, editors. Developmental Neuropathology of Schizophrenia. Boston: Springer US; 1991. pp. 93-120. [DOI: 10.1007/978-1-4615-3378-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 388 |
Robinson D, Mayerhoff D, Alvir J, Cooper T, Lieberman J. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology (Berl) 1991;105:247-52. [PMID: 1796130 DOI: 10.1007/BF02244317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 389 |
Lambert GW, Eisenhofer G, Cox HS, Horne M, Kalff V, Kelly M, Jennings GL, Esler MD. Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci 1991;49:1061-72. [PMID: 1895870 DOI: 10.1016/0024-3205(91)90593-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 390 |
Lal S, Nair NP, Thavundayil JX, Tawar V, Guyda H, Ayotte C. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:263-8. [PMID: 1871327 DOI: 10.1016/0278-5846(91)90090-n] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 391 |
Oakley NR, Hayes AG, Sheehan MJ. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology (Berl) 1991;105:204-8. [PMID: 1686655 DOI: 10.1007/BF02244310] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 392 |
Essig EC, Kilpatrick IC. Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology (Berl) 1991;104:194-200. [PMID: 1876664 DOI: 10.1007/BF02244178] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 393 |
Bogerts A, Falkai P, Degreef G, Lieberman JA. Neuropathological and Brain Imaging Studies in Positive and Negative Schizophrenia. Negative Versus Positive Schizophrenia 1991. [DOI: 10.1007/978-3-642-76841-5_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 394 |
Müller-spahn F. Literatur. Neuroendokrinologie und Schizophrenieforschung 1991. [DOI: 10.1007/978-3-642-84547-5_6] [Reference Citation Analysis]
|
| 395 |
Klimke A, Klieser E. The Treatment of Positive and Negative Schizophrenic Symptoms with Dopamine Agonists. Negative Versus Positive Schizophrenia 1991. [DOI: 10.1007/978-3-642-76841-5_23] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 396 |
Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Frajese G, Antonozzi I, Meltzer HY. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Psychiatry Res 1990;34:139-47. [PMID: 2149613 DOI: 10.1016/0165-1781(90)90015-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 397 |
Kulkarni J, Keks NA, Stuart G, Mackie B, Minas IH, Singh BS, Copolov DL. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release. Acta Psychiatr Scand 1990;82:271-4. [PMID: 2260479 DOI: 10.1111/j.1600-0447.1990.tb01383.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 398 |
Meltzer HY. Presynaptic receptors. Relevance to psychotropic drug action in man. Ann N Y Acad Sci 1990;604:353-71. [PMID: 1977354 DOI: 10.1111/j.1749-6632.1990.tb32005.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 399 |
Friedman E, Wang HY, Butkerait P. Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: modulation by cholinergic, dopamine-D1 and -D2 mechanisms. Neuropharmacology 1990;29:537-44. [PMID: 2200974 DOI: 10.1016/0028-3908(90)90065-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 400 |
Wachtel H, Turski L. Glutamate: a new target in schizophrenia? Trends Pharmacol Sci 1990;11:219-20. [PMID: 2166367 DOI: 10.1016/0165-6147(90)90243-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 401 |
Keks NA, Copolov DL, Kulkarni J, Mackie B, Singh BS, McGorry P, Rubin RT, Hassett A, McLaughlin M, van Riel R. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Biol Psychiatry 1990;27:1203-15. [PMID: 2354227 DOI: 10.1016/0006-3223(90)90418-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 402 |
Piazza PV, Calzà L, Giardino L, Amato G. Chronic thioridazine treatment differently affects DA receptors in striatum and in mesolimbo-cortical systems. Pharmacol Biochem Behav 1990;35:937-42. [PMID: 2345767 DOI: 10.1016/0091-3057(90)90382-r] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 403 |
Ashby CR Jr, Wang RY. Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res 1990;506:346-8. [PMID: 1967969 DOI: 10.1016/0006-8993(90)91278-o] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 404 |
Meltzer HY. Clozapine: Mechanism of Action in Relation to its Clinical Advantages. International Perspectives Series: Psychiatry, Psychology, and Neuroscience 1990. [DOI: 10.1007/978-1-4612-3248-3_11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 405 |
Gulya K. The opioid system in neurologic and psychiatric disorders and in their experimental models. Pharmacol Ther 1990;46:395-428. [PMID: 2188270 DOI: 10.1016/0163-7258(90)90026-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 406 |
Stefanis CN. On the Concept of Schizophrenia. Recent Advances in Schizophrenia. New York: Springer; 1990. pp. 25-57. [DOI: 10.1007/978-1-4612-3248-3_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 407 |
Hernandez L, Baptista T, Hoebel BG. Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats. Prog Neuropsychopharmacol Biol Psychiatry 1990;14 Suppl:S17-35. [PMID: 2097671 DOI: 10.1016/0278-5846(90)90084-t] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 408 |
Dewey SL, Brodie JD, Fowler JS, MacGregor RR, Schlyer DJ, King PT, Alexoff DL, Volkow ND, Shiue CY, Wolf AP. Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain. Synapse 1990;6:321-7. [PMID: 1981112 DOI: 10.1002/syn.890060403] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 409 |
Lal S, Nair NP, Isaac I, Thavundayil J, Guyda H. Effect of some peptides on dopaminergic function in man. J Neural Transm Suppl 1990;29:173-81. [PMID: 2113567 DOI: 10.1007/978-3-7091-9050-0_17] [Reference Citation Analysis]
|
| 410 |
Gelders YG. Die Bedeutung des 5-HT2-Rezeptor-Antagonismus für die Behandlung der Schizophrenie, unter spezieller Berücksichtigung der Minussymptomatik. Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik 1990. [DOI: 10.1007/978-3-642-76263-5_22] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 411 |
Dewey SL, MacGregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gatley SJ. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse 1990;5:213-23. [PMID: 2343375 DOI: 10.1002/syn.890050307] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 412 |
Rothman RB, Mele A, Reid AA, Akunne H, Greig N, Thurkauf A, Rice KC, Pert A. Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development. FEBS Lett 1989;257:341-4. [PMID: 2583282 DOI: 10.1016/0014-5793(89)81566-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 413 |
Perlmutter IR, Greenhill LL, Chambers W, Kestenbaum CJ. Childhood schizophrenia: theoretical and treatment issues. J Am Acad Child Adolesc Psychiatry 1989;28:956-62. [PMID: 2808271 DOI: 10.1097/00004583-198911000-00025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 414 |
Van Ree JM, Elands J, Király I, Wolterink G. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems. Eur J Pharmacol 1989;166:441-52. [PMID: 2572429 DOI: 10.1016/0014-2999(89)90357-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 415 |
Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989;238:332-9. [PMID: 2569975 DOI: 10.1007/BF00449814] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 416 |
Castelão JF, Ferreira L, Gelders YG, Heylen SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res 1989;2:411-5. [PMID: 2484825 DOI: 10.1016/0920-9964(89)90034-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 417 |
Grenhoff J, Svensson TH. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur J Pharmacol 1989;165:11-8. [PMID: 2569981 DOI: 10.1016/0014-2999(89)90765-6] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 418 |
Suzuki T, Moroji T. Cholecystokinin binding sites in the rat forebrain: effects of acute and chronic methamphetamine administration. J Neural Transm 1989;77:181-95. [PMID: 2760604 DOI: 10.1007/BF01248931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 419 |
Altar CA, Boyar WC. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Brain Res 1989;483:321-6. [PMID: 2706523 DOI: 10.1016/0006-8993(89)90176-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 420 |
Baker GB, Greenshaw AJ. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 1989;9:1-44. [PMID: 2565769 DOI: 10.1007/BF00711441] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 421 |
Lal S, Tesfaye Y, Thavundayil JX, Thompson TR, Kiely ME, Nair NP, Grassino A, Dubrovsky B. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:329-39. [PMID: 2748870 DOI: 10.1016/0278-5846(89)90122-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 422 |
Altar CA. Cholecystokinin receptor subtypes and neuromodulation. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:381-93. [PMID: 2748871 DOI: 10.1016/0278-5846(89)90127-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 423 |
Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99 Suppl:S18-27. [PMID: 2682729 DOI: 10.1007/BF00442554] [Cited by in Crossref: 404] [Cited by in F6Publishing: 419] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 424 |
Bibliography. Brain Messengers and the Pituitary 1989. [DOI: 10.1016/b978-0-12-510310-7.50013-2] [Reference Citation Analysis]
|
| 425 |
Greenshaw AJ, Baker GB, Wishart TB. Dopamine Receptor Changes During Chronic Drug Administration. Psychoactive Drugs 1989. [DOI: 10.1007/978-1-59259-464-1_7] [Reference Citation Analysis]
|
| 426 |
Freed WJ, Cannon-Spoor HE, Rodgers CR. Attenuation of the behavioral response to quisqualic acid and glutamic acid diethyl ester by chronic haloperidol administration. Life Sci 1989;44:1303-8. [PMID: 2654529 DOI: 10.1016/0024-3205(89)90368-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 427 |
Murray JB. Neuroleptic-resistant schizophrenics. J Psychol 1989;123:69-78. [PMID: 2564435 DOI: 10.1080/00223980.1989.10542963] [Reference Citation Analysis]
|
| 428 |
Nutt JG, Nilaver G, Hammerstad JP. The Blood-Brain Barrier and Movement Disorders. Implications of the Blood-Brain Barrier and Its Manipulation 1989. [DOI: 10.1007/978-1-4615-7255-8_8] [Reference Citation Analysis]
|
| 429 |
Huff FJ, Reiter CT, Rosen J, Peters J, van Kammen DP. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia. Biol Psychiatry 1988;24:701-4. [PMID: 3167152 DOI: 10.1016/0006-3223(88)90145-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 430 |
Lowe JA 3rd, Seeger TF, Vinick FJ. Atypical antipsychotics--recent findings and new perspectives. Med Res Rev 1988;8:475-97. [PMID: 2903950 DOI: 10.1002/med.2610080403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 431 |
Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Res 1988;25:233-42. [PMID: 2903509 DOI: 10.1016/0165-1781(88)90094-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 432 |
du Verglas G, Banks SR, Guyer KE. Clinical effects of fenfluramine on children with autism: a review of the research. J Autism Dev Disord 1988;18:297-308. [PMID: 3045076 DOI: 10.1007/BF02211954] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 433 |
Nisoli E, Grilli M, Memo M, Missale C, Spano PF. Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. Neurosci Lett 1988;87:247-52. [PMID: 2898117 DOI: 10.1016/0304-3940(88)90456-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 434 |
Kilts CD, Anderson CM, Bissette G, Ely TD, Nemeroff CB. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol 1988;37:1547-54. [PMID: 3358784 DOI: 10.1016/0006-2952(88)90017-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 435 |
Chiodo LA. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev 1988;12:49-91. [PMID: 3287242 DOI: 10.1016/s0149-7634(88)80073-3] [Cited by in Crossref: 191] [Cited by in F6Publishing: 199] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 436 |
Shepard PD, Mihailoff GA, German DC. Anatomical and electrophysiological characterization of presumed dopamine-containing neurons within the supramammillary region of the rat. Brain Res Bull 1988;20:307-14. [PMID: 2896530 DOI: 10.1016/0361-9230(88)90060-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 437 |
Csernansky JG, Mellentin J, Beauclair L, Lombrozo L. Mesolimbic dopaminergic supersensitivity following electrical kindling of the amygdala. Biol Psychiatry 1988;23:285-94. [PMID: 2962647 DOI: 10.1016/0006-3223(88)90039-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 438 |
Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988;22:141-55. [PMID: 3404482 DOI: 10.1016/0022-3956(88)90078-7] [Cited by in Crossref: 163] [Cited by in F6Publishing: 166] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 439 |
Mizuki Y, Ushijima I, Habu K, Nakamura K, Yamada M. Effects of ceruletide on clinical symptoms and EEGS in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:511-22. [PMID: 3406428 DOI: 10.1016/0278-5846(88)90110-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 440 |
Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:117-64. [PMID: 3290992 DOI: 10.1016/0278-5846(88)90033-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 441 |
Clark D, Chiodo LA. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat. Synapse 1988;2:474-85. [PMID: 2903568 DOI: 10.1002/syn.890020503] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 442 |
Stahl SM. Needs and opportunities for innovation in psychopharmacology. J R Soc Med 1987;80:413-7. [PMID: 3656311 DOI: 10.1177/014107688708000707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 443 |
Lane RF, Blaha CD. Acute thioridazine stimulates mesolimbic but not nigrostriatal dopamine release: demonstration by in vivo electrochemistry. Brain Res 1987;408:317-20. [PMID: 2439169 DOI: 10.1016/0006-8993(87)90396-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 444 |
Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52. [PMID: 2905529 DOI: 10.1002/syn.890010203] [Cited by in Crossref: 609] [Cited by in F6Publishing: 643] [Article Influence: 16.9] [Reference Citation Analysis]
|
| 445 |
Szewczak MR, Cornfeldt ML, Dunn RW, Wilker JC, Geyer HM, Fielding S, Glamkowski EJ, Chiang Y. Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent: 1. In vivo profile. Drug Dev Res 1987;11:157-68. [DOI: 10.1002/ddr.430110303] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 446 |
Pickar D, Breier A, Wolkowitz OM, Doran AR. The biochemical basis for the antipsychotic effects of neuroleptics. Etiopathogenetic Hypotheses of Schizophrenia 1987. [DOI: 10.1007/978-94-009-3207-4_19] [Reference Citation Analysis]
|
| 447 |
Rüther E, Müller-spahn F. Neurobiochemische Untersuchungen bei Akut- und Langzeitbehandlung mit Neuroleptika. Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen 1987. [DOI: 10.1007/978-3-642-83188-1_4] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 448 |
Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72. [PMID: 3790642 DOI: 10.1016/0006-3223(87)90131-4] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 449 |
van Ree JM, Verhoeven WM, de Wied D. Animal and clinical research on neuropeptides and schizophrenia. Prog Brain Res 1987;72:249-67. [PMID: 2441432 DOI: 10.1016/s0079-6123(08)60213-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 450 |
Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-33. [PMID: 2884687 DOI: 10.1007/BF00216006] [Cited by in Crossref: 361] [Cited by in F6Publishing: 367] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 451 |
Csernansky JG, Glick S, Mellentin J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. Psychopharmacology (Berl) 1987;91:440-4. [PMID: 3108924 DOI: 10.1007/BF00216008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 452 |
Bannon MJ, Freeman AS, Chiodo LA, Bunney BS, Roth RH. The Electrophysiological and Biochemical Pharmacology of the Mesolimbic and Mesocortical Dopamine Neurons. Handbook of Psychopharmacology 1987. [DOI: 10.1007/978-1-4613-1819-4_5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 453 |
Moroji T, Hagino Y. A behavioral pharmacological study on CCK-8 related peptides in mice. Neuropeptides 1986;8:273-86. [PMID: 3785587 DOI: 10.1016/0143-4179(86)90054-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 454 |
Siever LJ, van Kammen DP, Linnoila M, Alterman I, Hare T, Murphy DL. Smooth pursuit eye movement disorder and its psychobiologic correlates in unmedicated schizophrenics. Biol Psychiatry 1986;21:1167-74. [PMID: 3756265 DOI: 10.1016/0006-3223(86)90223-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 455 |
Davis KL, Fiori M, Davis BM, Mohs RC, Horvath TB, Davidson M. Dopaminergic dysregulation in schizophrenia: A target for new drugs. Drug Dev Res 1986;9:71-83. [DOI: 10.1002/ddr.430090109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 456 |
Csernansky JG, Prosser E, Kaplan J, Mahler E, Berger PA, Hollister LE. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. Biol Psychiatry 1986;21:632-42. [PMID: 2871874 DOI: 10.1016/0006-3223(86)90124-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 457 |
Anderson GD, Rebec GV. Differential response of amygdaloid neurons to clozapine and haloperidol: effects of repeated administration. Pharmacol Biochem Behav 1986;24:1561-6. [PMID: 3737625 DOI: 10.1016/0091-3057(86)90485-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 458 |
Antonian L, Joseph JA, Meyerson LR, Coupet J, Schuster DI, Katerinopoulos HE, Narula AP, Rauh CE. Striatally-mediated response of some structurally rigid analogues of dopamine. Pharmacol Biochem Behav 1986;24:253-8. [PMID: 3081915 DOI: 10.1016/0091-3057(86)90347-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 459 |
Kovelman JA, Scheibel AB. Biological substrates of schizophrenia. Acta Neurol Scand 1986;73:1-32. [PMID: 2869635 DOI: 10.1111/j.1600-0404.1986.tb03237.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 460 |
De Jesus OT, Friedman AM. Radiobrominated spiroperidol for the study of dopamine D2 receptors. Int J Rad Appl Instrum A 1986;37:719-26. [PMID: 3021673 DOI: 10.1016/0883-2889(86)90266-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 461 |
Nemeroff CB. The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 1986;11:15-37. [PMID: 2871577 DOI: 10.1016/0306-4530(86)90029-6] [Cited by in Crossref: 153] [Cited by in F6Publishing: 158] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 462 |
Davidson M, Kendler KS, Mohs RC, Hollander E, Ryan T, Davis KL. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. J Psychiatr Res 1986;20:131-5. [PMID: 3735141 DOI: 10.1016/0022-3956(86)90012-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 463 |
Nair NP, Lal S, Bloom DM. Cholecystokinin and schizophrenia. Prog Brain Res 1986;65:237-58. [PMID: 3538160 DOI: 10.1016/S0079-6123(08)60654-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 464 |
Stahl SM. Introduction Neuropharmacology of Movement Disorders. In: Shah NS, Donald AG, editors. Movement Disorders. Boston: Springer US; 1986. pp. 1-36. [DOI: 10.1007/978-1-4684-5038-5_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 465 |
van Ree JM, Verhoeven WM, Claas FH, de Wied D. Antipsychotic action of gamma-type endorphins: animal and human studies. Prog Brain Res 1986;65:221-35. [PMID: 2431435 DOI: 10.1016/S0079-6123(08)60653-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 466 |
Meltzer HY. Biological Studies of the Nosology of the Major Psychoses: A Status Report on the Schizoaffective Disorders. Schizoaffective Psychoses 1986. [DOI: 10.1007/978-3-642-71443-6_17] [Reference Citation Analysis]
|
| 467 |
Crosson B. Subcortical functions in language: a working model. Brain Lang 1985;25:257-92. [PMID: 3904918 DOI: 10.1016/0093-934x(85)90085-9] [Cited by in Crossref: 245] [Cited by in F6Publishing: 261] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 468 |
Csernansky JG, Csernansky CA, Bonnet KA, Hollister LE. Dopaminergic supersensitivity follows ferric chloride-induced limbic seizures. Biol Psychiatry 1985;20:723-33. [PMID: 4039950 DOI: 10.1016/0006-3223(85)90151-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 469 |
Rothschild AJ, Langlais PJ, Schatzberg AF, Miller MM, Saloman MS, Lerbinger JE, Cole JO, Bird ED. The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. Life Sci 1985;36:2491-501. [PMID: 2409422 DOI: 10.1016/0024-3205(85)90145-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 470 |
Moroji T, Itoh K, Itoh K. Antipsychotic effects of ceruletide in chronic schizophrenia. An appraisal of the long-term, intermittent medication of ceruletide in chronic schizophrenia. Ann N Y Acad Sci 1985;448:518-34. [PMID: 3927809 DOI: 10.1111/j.1749-6632.1985.tb29945.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 471 |
Pizzolato G, Soncrant TT, Larson DM, Rapoport SI. Reduced metabolic response of the rat brain to haloperidol after chronic treatment. Brain Res 1985;337:1-9. [PMID: 4039963 DOI: 10.1016/0006-8993(85)91604-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 472 |
Maas JW, Contreras SA, Bowden CL, Weintraub SE. Effects of debrisoquin on CSF and plasma HVA concentrations in man. Life Sci 1985;36:2163-70. [PMID: 3999921 DOI: 10.1016/0024-3205(85)90313-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 473 |
Szymanski HV, Orfanos A, Narisawa K, Grosz R, Naylor EW. Dihydropteridine reductase in schizophrenic patients. Psychiatry Res 1985;15:115-9. [PMID: 3862143 DOI: 10.1016/0165-1781(85)90047-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 474 |
Kamata K, Kameyama T. Effects of methamphetamine on dopamine cells in the substantia nigra pars compacta and the ventral tegmental area. Jpn J Pharmacol 1985;38:231-4. [PMID: 4032860 DOI: 10.1254/jjp.38.231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 475 |
Nasrallah HA. The unintegrated right cerebral hemispheric consciousness as alien intruder: a possible mechanism for Schneiderian delusions in schizophrenia. Compr Psychiatry 1985;26:273-82. [PMID: 3995938 DOI: 10.1016/0010-440x(85)90072-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 476 |
Cesarec Z, Nyman AK. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 1985;71:523-38. [PMID: 2861718 DOI: 10.1111/j.1600-0447.1985.tb05066.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 477 |
Kamata K, Rebec GV. Nigral reticulata neurons: potentiation of responsiveness to amphetamine with long-term treatment. Brain Res 1985;332:188-93. [PMID: 3995264 DOI: 10.1016/0006-8993(85)90406-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 478 |
Lawson WB, Karson CN, Bigelow LB. Increased urine volume in chronic schizophrenic patients. Psychiatry Res 1985;14:323-31. [PMID: 3860885 DOI: 10.1016/0165-1781(85)90100-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 479 |
Buchsbaum MS, Holcomb HH. Positron Emission Transaxial Tomography. Handbook of Psychiatric Diagnostic Procedures 1985. [DOI: 10.1007/978-94-011-6728-4_17] [Reference Citation Analysis]
|
| 480 |
Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl) 1985;85:329-32. [PMID: 3923519 DOI: 10.1007/BF00428197] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 481 |
Sternberg DE, Extein I. Studies of the Dopamine Hypothesis of Schizophrenia. The Catecholamines in Psychiatric and Neurologic Disorders 1985. [DOI: 10.1016/b978-0-409-95184-4.50020-5] [Reference Citation Analysis]
|
| 482 |
Castellani S, Petrie WM, Ellinwood E. Drug-Induced Psychosis. Applied Clinical Psychology 1985. [DOI: 10.1007/978-1-4899-3641-7_8] [Reference Citation Analysis]
|
| 483 |
Nair NP, Lal S, Bloom DM. Cholecystokinin peptides, dopamine and schizophrenia--a review. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:515-24. [PMID: 2868491 DOI: 10.1016/0278-5846(85)90011-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 484 |
Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19:57-64. [PMID: 2859366 DOI: 10.1016/0022-3956(85)90068-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 174] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 485 |
Csernansky JG, Csernansky CA, Hollister LE. Distinct effects of two stresses on the behavioral response to apomorphine. Life Sciences 1984;35:1513-8. [DOI: 10.1016/0024-3205(84)90169-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 486 |
Moss DE, Koob GF, McMaster SB, Janowsky DS. Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors. Pharmacol Biochem Behav 1984;21:641-4. [PMID: 6150497 DOI: 10.1016/s0091-3057(84)80050-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 487 |
DeLisi LE, Mirsky AF, Buchsbaum MS, van Kammen DP, Berman KF, Caton C, Kafka MS, Ninan PT, Phelps BH, Karoum F. The Genain Quadruplets 25 years later: a diagnostic and biochemical followup. Psychiatry Res 1984;13:59-76. [PMID: 6096907 DOI: 10.1016/0165-1781(84)90119-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 488 |
Luchins DJ, Robertson AG, Meltzer HY. Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia. Psychiatry Res 1984;12:149-53. [PMID: 6147869 DOI: 10.1016/0165-1781(84)90014-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 489 |
Lewine RJ, Meltzer HY. Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients. Psychiatry Res 1984;12:99-109. [PMID: 6591224 DOI: 10.1016/0165-1781(84)90010-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 490 |
Bunney BS. Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends in Neurosciences 1984;7:212-5. [DOI: 10.1016/s0166-2236(84)80013-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 491 |
Tueting P, Kaskey G, Buchsbaum M, Connolly J, Perris C, Roemer R. ERPs and psychopathology. II. Biological issues. Ann N Y Acad Sci 1984;425:523-45. [PMID: 6146279 DOI: 10.1111/j.1749-6632.1984.tb23574.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 492 |
van Ree JM, Gaffori O, Kiraly I. gamma-Endorphin and N alpha-acetyl-gamma-endorphin interfere with distinct dopaminergic systems in the nucleus accumbens via opioid and non-opioid mechanisms. Life Sci 1984;34:1317-24. [PMID: 6200747 DOI: 10.1016/0024-3205(84)90002-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 493 |
Verhoeven WM, van Ree JM, Westenberg HG, Krul JM, Brouwer GJ, Thijssen JH, de Wied D, van Praag HM, Ceulemans DL, Kahn RS. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia. Psychiatry Res 1984;11:329-46. [PMID: 6204351 DOI: 10.1016/0165-1781(84)90006-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 494 |
Carlton PL, Manowitz P. Dopamine and schizophrenia: an analysis of the theory. Neurosci Biobehav Rev 1984;8:137-51. [PMID: 6145134 DOI: 10.1016/0149-7634(84)90029-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 495 |
Haracz JL. A neural plasticity hypothesis of schizophrenia. Neurosci Biobehav Rev 1984;8:55-71. [PMID: 6145136 DOI: 10.1016/0149-7634(84)90020-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 496 |
Rebec GV, Bashore TR. Critical issues in assessing the behavioral effects of amphetamine. Neurosci Biobehav Rev 1984;8:153-9. [PMID: 6145135 DOI: 10.1016/0149-7634(84)90030-7] [Cited by in Crossref: 121] [Cited by in F6Publishing: 125] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 497 |
Müller-Spahn F, Ackenheil M, Albus M, May G, Naber D, Welter D, Zander K. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia. Psychopharmacology (Berl) 1984;84:436-40. [PMID: 6151210 DOI: 10.1007/BF00555228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 498 |
Nedopil N, Weiss-brummer J, Rüther E. Neuroendocrine Changes during the Course of Neuroleptic Treatment of Schizophrenic Patients. Psychoneuroendocrine Dysfunction 1984. [DOI: 10.1007/978-1-4684-4529-9_33] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 499 |
Van Oot PH, Lane TW, Borkovec TD. Sleep Disturbances. Comprehensive Handbook of Psychopathology 1984. [DOI: 10.1007/978-1-4615-6681-6_24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 500 |
Singh MM, Kay SR. Exogenous Peptides and Schizophrenia. Psychoneuroendocrine Dysfunction 1984. [DOI: 10.1007/978-1-4684-4529-9_30] [Reference Citation Analysis]
|
| 501 |
Pandey GN, Casper R, Davis JM, Ali SI. Neuroendocrine Studies in Schizophrenia. Psychoneuroendocrine Dysfunction 1984. [DOI: 10.1007/978-1-4684-4529-9_29] [Reference Citation Analysis]
|
| 502 |
Lal S, Nair NPV. Neuroendocrine Evaluation of Catecholaminergic Function in Man. Psychoneuroendocrine Dysfunction 1984. [DOI: 10.1007/978-1-4684-4529-9_28] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 503 |
Freed WJ, Hoffer BJ, Olson L, Wyatt RJ. Transplantation of Catecholamine-Containing Tissues to Restore the Functional Capacity of the Damaged Nigrostriatal System. In: Sladek JR, Gash DM, editors. Neural Transplants. Boston: Springer US; 1984. pp. 373-406. [DOI: 10.1007/978-1-4684-4685-2_16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 504 |
Wachtel H, Kehr W, Sauer G. Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride. Life Sci 1983;33:2583-97. [PMID: 6607392 DOI: 10.1016/0024-3205(83)90342-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 505 |
Lehmann J, Langer SZ. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience 1983;10:1105-20. [PMID: 6320043 DOI: 10.1016/0306-4522(83)90102-1] [Cited by in Crossref: 365] [Cited by in F6Publishing: 377] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 506 |
Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization. Neuroscience 1983;10:301-15. [PMID: 6633863 DOI: 10.1016/0306-4522(83)90135-5] [Cited by in Crossref: 676] [Cited by in F6Publishing: 759] [Article Influence: 16.9] [Reference Citation Analysis]
|
| 507 |
Lal S, Nair NP, Thavundayil JX, Monks RC, Guyda H. Clonidine-induced growth hormone secretion in chronic schizophrenia. Acta Psychiatr Scand 1983;68:82-8. [PMID: 6137940 DOI: 10.1111/j.1600-0447.1983.tb06985.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 508 |
Orzi F, Dow-Edwards D, Jehle J, Kennedy C, Sokoloff L. Comparative effects of acute and chronic administration of amphetamine on local cerebral glucose utilization in the conscious rat. J Cereb Blood Flow Metab 1983;3:154-60. [PMID: 6841462 DOI: 10.1038/jcbfm.1983.22] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 509 |
Schneider SJ. Multiple measures of hemispheric dysfunction in schizophrenia and depression. Psychol Med 1983;13:287-97. [PMID: 6878515 DOI: 10.1017/s003329170005090x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 510 |
Weinberger DR, Wyatt RJ. Enlarged Cerebral Ventricles in Schizophrenia. Psychiatric Annals 1983;13:412-8. [DOI: 10.3928/0048-5713-19830501-06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 511 |
Krieger NR, Megill JR, Sterling P. Granule cells in the rat olfactory tubercle accumulate 3H-gamma-aminobutyric acid. J Comp Neurol 1983;215:465-71. [PMID: 6134758 DOI: 10.1002/cne.902150410] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 512 |
Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioural and biochemical effects of chronic treatment with amphetamine in the vervet monkey. Neuropharmacology 1983;22:551-4. [PMID: 6682939 DOI: 10.1016/0028-3908(83)90178-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 513 |
Venables P. Some Problems and Controversies in the Psychophysiological Investigation of Schizophrenia. Individual Differences and Psychopathology 1983. [DOI: 10.1016/b978-0-12-273903-3.50018-3] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 514 |
Nestoros JN, Nair NP, Pulman JR, Schwartz G, Bloom D. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology (Berl) 1983;81:42-7. [PMID: 6138791 DOI: 10.1007/BF00439272] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 515 |
Nemeroff CB, Luttinger D, Prange AJ. Neurotensin and Bombesin. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of Psychopharmacology. Boston: Springer US; 1983. pp. 363-466. [DOI: 10.1007/978-1-4613-3515-3_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 516 |
Bürki HR, Gaertner HJ, Breyer-pfaff U, Schied HW. Neuroleptika: Grundlagen und Therapie. Psychopharmaka 1983. [DOI: 10.1007/978-3-7091-7645-0_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 517 |
Hoebel BG, Monaco AP, Hernandez L, Aulisi EF, Stanley BG, Lenard L. Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) 1983;81:158-63. [PMID: 6415748 DOI: 10.1007/BF00429012] [Cited by in Crossref: 278] [Cited by in F6Publishing: 287] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 518 |
van Ree JM, Verhoeven WM, de Wied D, van Praag HM. The use of the synthetic peptides gamma-type endorphins in mentally ill patients. Ann N Y Acad Sci 1982;398:478-95. [PMID: 6186176 DOI: 10.1111/j.1749-6632.1982.tb39519.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 519 |
Schulz SC, van Kammen DP, Pickar D, Cohen MR, Naber D. Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Res 1982;7:171-8. [PMID: 6292981 DOI: 10.1016/0165-1781(92)90090-p] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 520 |
De Wied D. Neuropeptides and psychopathology. Eur J Clin Invest 1982;12:281-4. [PMID: 6291950 DOI: 10.1111/j.1365-2362.1982.tb02233.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 521 |
Thermos K, Murphy RB, Schuster DI. Photoincorporation of [3H]-chloropromazine into a solubilized bovine striatal preparation. Biochem Biophys Res Commun 1982;106:1469-77. [PMID: 7115414 DOI: 10.1016/0006-291x(82)91279-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 522 |
Buccafusco JJ. Kinetics of [3H]choline and [3H]acetylcholine metabolism in several regions of rat brain following intracerebroventricular injection of [3H]choline. Effects of haloperidol. Biochem Pharmacol 1982;31:1599-605. [PMID: 7092951 DOI: 10.1016/0006-2952(82)90387-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 523 |
Garbutt JC, van Kammen DP, Levine RA, Sternberg DE, Murphy DL, Ballenger J, Bunney WE Jr, Lovenberg WM. Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Res 1982;6:145-51. [PMID: 6953456 DOI: 10.1016/0165-1781(82)90002-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 524 |
Katz LD. Hedonic arousal, memory, and motivation. Behav Brain Sci 1982;5:60-60. [DOI: 10.1017/s0140525x0001044x] [Reference Citation Analysis]
|
| 525 |
Lyons W. The anhedonia vs the eclectic hypothesis. Behav Brain Sci 1982;5:65-66. [DOI: 10.1017/s0140525x00010505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 526 |
Tombaugh TN. A discriminating case against anhedonia. Behav Brain Sci 1982;5:77-78. [DOI: 10.1017/s0140525x0001061x] [Reference Citation Analysis]
|
| 527 |
Klemm WR. Time for a new synthesis of hedonia mechanisms: Interaction of multiple and interdependent reinforcer systems. Behav Brain Sci 1982;5:61-63. [DOI: 10.1017/s0140525x00010463] [Reference Citation Analysis]
|
| 528 |
Lyness WH. Dopaminergic and serotonergic influence on d-amphetamine self-administration: Alterations of reward perception. Behav Brain Sci 1982;5:65-65. [DOI: 10.1017/s0140525x00010499] [Reference Citation Analysis]
|
| 529 |
Mellgren RL. The anhedonia hypothesis: Termites in the basement. Behav Brain Sci 1982;5:67-68. [DOI: 10.1017/s0140525x00010529] [Reference Citation Analysis]
|
| 530 |
Schuster DI, Holden WL, Narula AP, Murphy RB. Irreversible blockade of striatal dopamine receptors in vivo by a derivative of alpha-flupenthixol. Eur J Pharmacol 1982;77:313-6. [PMID: 7060641 DOI: 10.1016/0014-2999(82)90134-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 531 |
Ridley RM, Baker HF. Stereotypy in monkeys and humans. Psychol Med 1982;12:61-72. [PMID: 6805001 DOI: 10.1017/s0033291700043294] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 532 |
Fields JZ, Gordon JH. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sci 1982;30:229-34. [PMID: 7200183 DOI: 10.1016/0024-3205(82)90503-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 533 |
Versteeg DH, Kovács GL, Bohus B, de Kloet ER, de Wied D. Effect of des-Tyr1-gamma-endorphin and des-Tyr1-alpha-endorphin on alpha-MPT-induced catecholamine disappearance in rat brain nuclei: a dose--response study. Brain Res 1982;231:343-51. [PMID: 6120024 DOI: 10.1016/0006-8993(82)90371-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 534 |
Meltzer HY. Dopamine autoreceptor stimulation: clinical significance. Pharmacol Biochem Behav 1982;17 Suppl 1:1-10. [PMID: 6223322 DOI: 10.1016/0091-3057(82)90504-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 535 |
Nair NP, Bloom DM, Nestoros JN. Cholecystokinin appears to have antipsychotic properties. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:509-12. [PMID: 6891817 DOI: 10.1016/s0278-5846(82)80140-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 536 |
Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacology (Berl) 1982;78:245-51. [PMID: 6130556 DOI: 10.1007/BF00428159] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 537 |
Nestoros JN, Suranyi-Cadotte BE, Spees RC, Schwartz G, Nair NP. Diazepam in high doses is effective in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:513-6. [PMID: 6891818 DOI: 10.1016/s0278-5846(82)80141-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 538 |
Struve FA, Ramsey PP, Kane JM, Willner AE. Neuropsychological and Electroencephalographic Correlates of Neuroleptic Induced Involuntary Movements: Implications for Tardive Dyskinesia. Neuropsychology and Cognition — Volume I / Volume II 1982. [DOI: 10.1007/978-94-009-7654-2_56] [Reference Citation Analysis]
|
| 539 |
Metz J, Holcomb HH, Meltzer HY. Effect of chlorpromazine on H-reflex recovery curves in normal subjects and schizophrenic patients. Psychopharmacology (Berl) 1982;78:342-5. [PMID: 6818596 DOI: 10.1007/BF00433738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 540 |
Marshall WL. A Model of Dysfunctional Behavior. International Handbook of Behavior Modification and Therapy 1982. [DOI: 10.1007/978-1-4615-7275-6_3] [Cited by in Crossref: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 541 |
Weinberger D, Wyatt R. CEREBRAL VENTRICULAR SIZE: A BIOLOGICAL MARKER FOR SUB-TYPING CHRONIC SCHIZOPHRENIA. Biological Markers in Psychiatry and Neurology. Elsevier; 1982. pp. 505-12. [DOI: 10.1016/b978-0-08-027987-9.50054-8] [Cited by in Crossref: 18] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 542 |
De Wied D. Pro-opio(melano)cortin and brain homeostasis. Prog Brain Res 1982;55:473-82. [PMID: 6298866 DOI: 10.1016/S0079-6123(08)64216-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 543 |
Kokkinidis L, Anisman H. Amphetamine psychosis and schizophrenia: a dual model. Neurosci Biobehav Rev 1981;5:449-61. [PMID: 7033842 DOI: 10.1016/0149-7634(81)90015-4] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 544 |
Dourish CT. Behavioural effects of acute and chronic beta-phenylethylamine administration in the rat: evidence for the involvement of 5-hydroxytryptamine. Neuropharmacology 1981;20:1067-72. [PMID: 7322283 DOI: 10.1016/0028-3908(81)90098-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 545 |
Nestoros JN, Lehmann HE, Ban TA. Sexual behavior of the male schizophrenic: the impact of illness and medications. Arch Sex Behav 1981;10:421-42. [PMID: 6119066 DOI: 10.1007/BF01541435] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 546 |
Rastogi RB, Singhal RL, Lapierre YD. Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: focus on the serotonin hypothesis of schizophrenia. Life Sci 1981;29:735-41. [PMID: 6168884 DOI: 10.1016/0024-3205(81)90027-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 547 |
Asnis GM, Sachar EJ, Halbreich U, Ostrow LC, Nathan RS, Halpern FS. The prolactin-stimulating potency of reserpine in man. Psychiatry Res 1981;5:39-45. [PMID: 6944708 DOI: 10.1016/0165-1781(81)90059-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 548 |
Meltzer HY, Busch DA, Creese IR, Snyder SH, Fang VS. Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. Psychiatry Res 1981;5:95-105. [PMID: 6944710 DOI: 10.1016/0165-1781(81)90065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 549 |
Reisine T. Adaptive changes in catecholamine receptors in the central nervous system. Neuroscience 1981;6:1471-502. [PMID: 6115335 DOI: 10.1016/0306-4522(81)90221-9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 103] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 550 |
Castellani S, Adams PM. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 1981;73:143-54. [PMID: 7198045 DOI: 10.1016/0014-2999(81)90086-8] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 551 |
Meltzer HY, Simonovic M, Sturgeon RD, Fang VS. Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatr Scand Suppl 1981;290:100-21. [PMID: 6971560 DOI: 10.1111/j.1600-0447.1981.tb00713.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 552 |
DeLisi LE, Wise CD, Bridge TP, Rosenblatt JE, Wagner RL, Morihisa J, Karson C, Potkin SG, Wyatt RJ. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Res 1981;4:95-107. [PMID: 6111821 DOI: 10.1016/0165-1781(81)90013-5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 553 |
Schlemmer RF Jr, Davis JM. Evidence for dopamine mediation of submissive gestures in the stumptail macaque monkey. Pharmacol Biochem Behav 1981;14 Suppl 1:95-102. [PMID: 7243853 DOI: 10.1016/s0091-3057(81)80016-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 554 |
Krieger NR. Neurochemistry of the Olfactory Tubercle. Biochemistry of Taste and Olfaction 1981. [DOI: 10.1016/b978-0-12-154450-8.50029-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 555 |
van Kammen D, Post R, Bunney W, Sternberg D, Hare T, Ballenger J, Marder S. SPINAL FLUID GABA LEVELS IN SCHIZOPHRENIA. Recent Advances in Neuropsycho-Pharmacology 1981. [DOI: 10.1016/b978-0-08-026382-3.50045-1] [Cited by in Crossref: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 556 |
Schlemmer R, Davis J. SIMILARITIES IN THE BEHAVIORAL EFFECTS OF d-AMPHETAMINE AND APOMORPHINE IN SELECTED MEMBERS OF A PRIMATE SOCIAL COLONY. Recent Advances in Neuropsycho-Pharmacology. Elsevier; 1981. pp. 3-12. [DOI: 10.1016/b978-0-08-026382-3.50005-0] [Cited by in Crossref: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 557 |
Meltzer HY, Busch D, Fang VS. Hormones, dopamine receptors and schizophrenia. Psychoneuroendocrinology 1981;6:17-36. [PMID: 7244055 DOI: 10.1016/0306-4530(81)90045-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 558 |
deVito RA, Marozas RJ. The alcoholic Satyr. Sex Disabil 1981;4:234-45. [DOI: 10.1007/bf01103308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 559 |
Dotti A, Lostia O, Rubino IA, Bersant G, Carilli L, Zorreta D. The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate. Prog Neuropsychopharmacol 1981;5:69-77. [PMID: 7280130 DOI: 10.1016/0364-7722(81)90007-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 560 |
Katz RJ, Schmaltz K. Dopaminergic involvement in attention. A novel animal model. Prog Neuropsychopharmacol 1980;4:585-90. [PMID: 7220672 DOI: 10.1016/0364-7722(81)90099-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 561 |
Van Ree JM, De Wied D. Brain Peptides and Psychoactive Drug Effects. Research Advances in Alcohol and Drug Problems 1981. [DOI: 10.1007/978-1-4615-7740-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 562 |
Creese I. Dopamine Receptors. In: Yamamura HI, Enna SJ, editors. Neurotransmitter Receptors. Dordrecht: Springer Netherlands; 1981. pp. 129-83. [DOI: 10.1007/978-94-009-5928-6_4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 563 |
Van Der Meer YG, Van Loenen AC. Dopamine en farmaca. Pharmaceutisch Weekblad Scientific Edition 1980;2:1637-1646. [DOI: 10.1007/bf02273426] [Reference Citation Analysis]
|
| 564 |
Frey WH 2nd, Senogles SE, Heston LL, Tuason VB, Nicol SE. Catecholamine-sensitive guanylate cyclase from human caudate nucleus. J Neurochem 1980;35:1418-30. [PMID: 6108353 DOI: 10.1111/j.1471-4159.1980.tb09018.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 565 |
Sloviter RS, Connor JD, Drust EG. Serotonergic properties of beta-phenethylamine in rats. Neuropharmacology 1980;19:1071-4. [PMID: 6449675 DOI: 10.1016/0028-3908(80)90103-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 566 |
Nielsen EB, Nielsen M, Ellison G, Braestrup C. Decreased spiroperidol and LSD binding in rat brain after continuous amphetamine. Eur J Pharmacol 1980;66:149-54. [PMID: 7439269 DOI: 10.1016/0014-2999(80)90137-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 567 |
Metz J, Goode DJ, Meltzer HY. Descriptive studies of H-reflex recovery curves in psychiatric patients. Psychol Med 1980;10:541-8. [PMID: 6108587 DOI: 10.1017/s0033291700047437] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 568 |
Doherty JD, Simonovic M, So R, Meltzer HY. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum. Eur J Pharmacol 1980;65:139-49. [PMID: 7398783 DOI: 10.1016/0014-2999(80)90386-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 569 |
Erard R, Luisada PV, Peele R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs 1980;12:235-51. [PMID: 7431420 DOI: 10.1080/02791072.1980.10471432] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 570 |
Wheeler SC, Roth RH. Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment. Naunyn Schmiedebergs Arch Pharmacol 1980;312:151-9. [PMID: 7190650 DOI: 10.1007/BF00569724] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 571 |
Heinz GH, Hill EF, Contrera JF. Dopamine and norepinephrine depletion in ring doves fed DDE, dieldrin, and Aroclor 1254. Toxicol Appl Pharmacol 1980;53:75-82. [PMID: 6770493 DOI: 10.1016/0041-008x(80)90383-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 572 |
Quitkin FM, Rifkin A, Tsuang MT, Kane JM, Klein DF. Can schizophrenia with premorbid asociality be genetically distinguished from the other forms of schizophrenia? Psychiatry Res 1980;2:99-105. [PMID: 6932057 DOI: 10.1016/0165-1781(80)90010-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 573 |
van Kammen DP, Sternberg DE. Cerebrospinal Fluid Studies in Schizophrenia. In: Wood JH, editor. Neurobiology of Cerebrospinal Fluid 1. Boston: Springer US; 1980. pp. 719-42. [DOI: 10.1007/978-1-4684-1039-6_48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 574 |
Strauss JS, Docherty JP, Downey TW. Toward Comprehensive Understanding and Treatment of Schizophrenia. The Psychotherapy of Schizophrenia 1980. [DOI: 10.1007/978-1-4684-3770-6_24] [Reference Citation Analysis]
|
| 575 |
Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl) 1980;72:17-9. [PMID: 6110217 DOI: 10.1007/BF00433802] [Cited by in Crossref: 252] [Cited by in F6Publishing: 249] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 576 |
Carlsson A. Psychopharmacology: Basic Aspects. In: Angst J, Carlsson A, Gross J, Jung R, Kempe P, Künkel H, Laitinen L, Matussek N, Ottosson J, Ploog D, Richter D, Woggon B, Zerbin-rüdin E, von Zerssen D, editors. Grundlagen und Methoden der Psychiatrie. Berlin: Springer Berlin Heidelberg; 1980. pp. 197-242. [DOI: 10.1007/978-3-642-67416-7_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 577 |
Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 1980;5:121-37. [PMID: 6104835 DOI: 10.1016/0306-4530(80)90015-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 578 |
Reisine T, Pedigo N, Regan P, Ling N, Yamamura H. ABNORMAL BRAIN OPIATE MECHANISMS IN SCHIZOPHRENIA. Endogenous and Exogenous Opiate Agonists and Antagonists 1980. [DOI: 10.1016/b978-0-08-025488-3.50035-0] [Reference Citation Analysis]
|
| 579 |
Van Kammen DP, Sternberg DE, Hare TA, Ballenger JC, Marder SR, Post RM, Bunney WE. Schizophrenia: Low spinal fluid GABA levels? Brain Research Bulletin 1980;5:731-5. [DOI: 10.1016/0361-9230(80)90120-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 580 |
Antelman SM, Caggiula AR. Stress-Induced Behavior: Chemotherapy without Drugs. The Psychobiology of Consciousness 1980. [DOI: 10.1007/978-1-4684-3456-9_4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 581 |
Krieger NR, Bunney BS, Greengard P. Localization of dopamine-sensitive adenylate cyclase activity within laminae of the rat prefrontal cortex. Brain Res 1979;179:171-5. [PMID: 509228 DOI: 10.1016/0006-8993(79)90502-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 582 |
Van Ree JM, De Wied D. Endorfinen en hun betekenis voor de psychopathologie. Pharmaceutisch Weekblad Scientific Edition 1979;1:221-230. [DOI: 10.1007/bf02293188] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 583 |
Sturgeon RD, Fessler RG, Meltzer HY. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979;59:169-79. [PMID: 575093 DOI: 10.1016/0014-2999(79)90279-6] [Cited by in Crossref: 191] [Cited by in F6Publishing: 198] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 584 |
Rosenfeld MR, Seeger TF, Sharpless NS, Gardner EL, Makman MH. Denervation supersensitivity in the mesolimbic system: involvement of dopamine-stimulated adenylate cyclase. Brain Res 1979;173:572-6. [PMID: 487111 DOI: 10.1016/0006-8993(79)90255-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 585 |
Meltzer HY, So R, Miller RJ, Fang VS. Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion. Life Sci 1979;25:573-83. [PMID: 41148 DOI: 10.1016/0024-3205(79)90551-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 586 |
Domino EF, Mathews BN, Tait SK. Urinary neurotransmitter metabolites in drug-free chronic schizophrenic patients measured by gas chromatography selected positive ion monitoring. Biomed Mass Spectrom 1979;6:331-4. [PMID: 40628 DOI: 10.1002/bms.1200060804] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 587 |
Struve FA, Kane JM, Wegner JT, Kantor J. Relationship of mitten patterns to neuroleptic drug induced dyskinesias in psychiatric patients: early investigative findings. Clin Electroencephalogr 1979;10:151-63. [PMID: 38924 DOI: 10.1177/155005947901000304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 588 |
Joseph MH, Frith CD, Waddington JL. Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model. Psychopharmacology (Berl) 1979;63:273-80. [PMID: 113814 DOI: 10.1007/BF00433561] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 589 |
Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS. Effect of d- and l-amphetamine on rat plasma prolactin levels. Psychopharmacology (Berl) 1979;61:63-9. [PMID: 108721 DOI: 10.1007/BF00426812] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 590 |
Maas JW, Hattox SE, Martin DM, Landis DH. A direct method for determining dopamine synthesis and output of dopamine metabolites from brain in awake animals. J Neurochem 1979;32:839-43. [PMID: 107275 DOI: 10.1111/j.1471-4159.1979.tb04568.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 591 |
Svensson TH. Psykos och dyskinesi vid amfetaminism: Patofysiologiska mekanismer. Nordisk Psykiatrisk Tidsskrift 1979;33:443-449. [DOI: 10.3109/08039487909103167] [Reference Citation Analysis]
|
| 592 |
Kleinman JE, Bridge P, Karoum F, Speciale S, Staub R, Zalcman S, Gillin JC, Wyatt RJ. CATECHOLAMINES AND METABOLITES IN THE BRAINS OF PSYCHOTICS AND NORMALS: POST-MORTEM STUDIES. Catecholamines: Basic and Clinical Frontiers. Elsevier; 1979. pp. 1845-7. [DOI: 10.1016/b978-1-4832-8363-0.50566-8] [Cited by in Crossref: 8] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 593 |
de Wied D. Schizophrenia as an inborn error in the degradation of β-endorphin — a hypothesis. Trends in Neurosciences 1979;2:79-82. [DOI: 10.1016/0166-2236(79)90033-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 594 |
van Kammen DP. The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 1979;4:37-46. [PMID: 39306 DOI: 10.1016/0306-4530(79)90039-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 595 |
Wechsler LR, Savaki HE, Sokoloff L. Effects of d- and l-amphetamine on local cerebral glucose utilization in the conscious rat. J Neurochem 1979;32:15-22. [PMID: 759566 DOI: 10.1111/j.1471-4159.1979.tb04504.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 154] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 596 |
Nicol SE, Heston LL. The Future of Genetic Research in Schizophrenia. Psychiatric Annals 1979;9:32-53. [DOI: 10.3928/0048-5713-19790101-05] [Reference Citation Analysis]
|
| 597 |
van Kammen DP, Bunney WE. HETEROGENEITY IN RESPONSE TO AMPHETAMINE IN SCHIZOPHRENIA: EFFECTS OF PLACEBO, CHRONIC PIMOZIDE AND PIMOZIDE WITHDRAWAL. Catecholamines: Basic and Clinical Frontiers. Elsevier; 1979. pp. 1896-8. [DOI: 10.1016/b978-1-4832-8363-0.50583-8] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 598 |
Schlemmer RF Jr, Jackson JA, Preston KL, Bederka JP Jr, Garver DL, Davis JM. Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur J Pharmacol 1978;52:379-84. [PMID: 103731 DOI: 10.1016/0014-2999(78)90293-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 599 |
Bunney BS, Grace AA. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978;23:1715-27. [PMID: 31529 DOI: 10.1016/0024-3205(78)90471-x] [Cited by in Crossref: 448] [Cited by in F6Publishing: 459] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 600 |
van Kammen DP, Docherty JP, Marder SR, Siris SG, Bunney WE Jr. d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment. Life Sci 1978;23:1487-92. [PMID: 362103 DOI: 10.1016/0024-3205(78)90130-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 601 |
Wagner JA. The Organizational Double Bind: Toward an Understanding of Rationality and Its Complement. AMR 1978;3:786-95. [DOI: 10.5465/amr.1978.4289283] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 602 |
Russell RL, Pihl RO. Determinants of amphetamine-produced stereotyped behavior in the rat. Psychol Rep 1978;43:575-9. [PMID: 569344 DOI: 10.2466/pr0.1978.43.2.575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 603 |
Meltzer HY, Simonovic M, Fang V, Piyakalamala S, Young M. A comparison of the effects of anti-psychotic drugs on pituitary, striatal and limbic system post-synaptic dopamine receptors. Life Sci 1978;23:605-9. [PMID: 29199 DOI: 10.1016/0024-3205(78)90040-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 604 |
Alpert M, Diamond F, Weisenfreund J, Taleporos E, Friedhoff AJ. The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects. Br J Psychiatry 1978;133:169-75. [PMID: 354734 DOI: 10.1192/bjp.133.2.169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 605 |
Colpaert FC, Niemegeers CJ, Janssen PA. Neuroleptic interference with the cocaine cue: internal stimulus control of behavior and psychosis. Psychopharmacology (Berl) 1978;58:247-55. [PMID: 28546 DOI: 10.1007/BF00427387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 606 |
Hart WG. Reply to a case report by Ian Sale and Henry Kristall--March issue. Aust N Z J Psychiatry 1978;12:136-7. [PMID: 278605 DOI: 10.3109/00048677809159608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 607 |
Stahl SM, Meltzer HY. The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. Exp Neurol 1978;59:1-15. [PMID: 627258 DOI: 10.1016/0014-4886(78)90196-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 608 |
Roth JA, Feor K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem Pharmacol 1978;27:1606-8. [PMID: 697902 DOI: 10.1016/0006-2952(78)90493-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 609 |
Venables PH. COMMENTARY. Event-Related Brain Potentials in Man 1978. [DOI: 10.1016/b978-0-12-155150-6.50023-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 610 |
Maas JW, Hattox SE, Landis DH, Roth RH. A direct method for studying 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) production by brain in awake animals. Eur J Pharmacol 1977;46:221-8. [PMID: 412681 DOI: 10.1016/0014-2999(77)90337-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 611 |
Fields JZ, Reisine TD, Yamamura HI. Biochemical demonstration of dopaminergic receptors in rat and human brain using [3H]spiroperidol. Brain Res 1977;136:578-84. [PMID: 922503 DOI: 10.1016/0006-8993(77)90084-1] [Cited by in Crossref: 270] [Cited by in F6Publishing: 273] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 612 |
Bladessarini RJ. Schizophrenia. N Engl J Med 1977;297:988-95. [PMID: 20577 DOI: 10.1056/NEJM197711032971807] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 613 |
Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977;7:583-97. [PMID: 22890 DOI: 10.1017/s003329170000622x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 614 |
Hartmann E, Keller-Teschke M. Biology of schizophrenia: Mental effects of dopamine-beta-hydroxylase inhibition in normal men. Lancet 1977;1:37-8. [PMID: 63668 DOI: 10.1016/s0140-6736(77)91668-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
|
